

Grape King Bio Ltd. and Subsidiaries

**Consolidated Financial Statements for the
Three Months Ended March 31, 2025 and 2024 and
Independent Auditors' Review Report**

INDEPENDENT AUDITORS' REVIEW REPORT

The Board of Directors and Shareholders
Grape King Bio Ltd.

Introduction

We have reviewed the accompanying consolidated balance sheets of Grape King Bio Ltd. (the “Company”) and its subsidiaries (collectively, the “Group”) as of March 31, 2025 and 2024, the related consolidated statements of comprehensive income, the consolidated statements of changes in equity and cash flows for the three months ended March 31, 2025 and 2024, and the related notes to the consolidated financial statements, including material accounting policy information (collectively referred to as the “consolidated financial statements”). Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34 “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.


Scope of Review

We conducted our reviews in accordance with the Standards on Review Engagements of the Republic of China 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews, nothing has come to our attention that caused us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as of March 31, 2025 and 2024 and its consolidated financial performance and its consolidated cash flows for the three months ended March 31, 2025 and 2024 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34 “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

The engagement partners on the reviews resulting in this independent auditors' review report are Ming Yuan Chung and Chih Yuan Wen.



Deloitte & Touche
Taipei, Taiwan
Republic of China

May 9, 2025

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' review report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' review report and consolidated financial statements shall prevail.

CONSOLIDATED BALANCE SHEETS
(In Thousands of New Taiwan Dollars)

LIABILITIES AND EQUITY	March 31, 2025		December 31, 2024		March 31, 2024	
	Amount	%	Amount	%	Amount	%
CURRENT LIABILITIES						
Contract liabilities (Notes 23 and 31)	\$ 86,988	1	\$ 142,052	1	\$ 138,240	1
Notes and accounts payable	313,975	2	306,317	2	301,003	2
Accounts payable to related parties (Note 31)	7,165	-	3,127	-	4,087	-
Other payables (Note 19)	2,173,658	15	2,403,427	16	1,611,890	10
Other payables to related parties (Note 31)	41,425	-	34,393	-	45,625	-
Current tax liabilities (Note 25)	404,588	3	340,417	2	1,147,993	7
Lease liabilities (Notes 15 and 31)	72,027	-	53,948	1	56,813	1
Other current liabilities (Notes 19 and 31)	34,447	-	39,362	-	18,940	-
Total current liabilities	3,134,273	21	3,323,043	22	3,324,591	21
NON-CURRENT LIABILITIES						
Provisions (Note 20)	10,297	-	9,826	-	9,760	-
Deferred tax liabilities (Note 25)	84,490	1	82,730	-	79,399	1
Lease liabilities (Notes 15 and 31)	172,801	1	106,963	1	128,986	1
Other non-current liabilities (Notes 19 and 31)	10,322	-	10,381	-	11,008	-
Total non-current liabilities	277,910	2	209,900	1	229,153	2
Total liabilities	3,412,183	23	3,532,943	23	3,553,744	23
EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY (Note 22)						
Share capital						
Ordinary shares	1,481,374	10	1,481,374	10	1,481,374	10
Capital surplus	2,878,597	19	2,878,597	19	2,878,597	18
Retained earnings						
Legal reserve	1,678,017	11	1,678,017	11	1,474,160	9
Special reserve	47,543	1	47,543	-	70,828	1
Unappropriated earnings	3,590,399	24	4,004,929	26	4,413,029	28
Total retained earnings	5,315,959	36	5,730,489	37	5,958,017	38
Other equity	(9,184)	-	(34,761)	-	(57,999)	-
Total equity attributable to owners of the Company	9,666,746	65	10,055,699	66	10,259,989	66
NON-CONTROLLING INTERESTS (Notes 12 and 22)	1,860,874	12	1,734,996	11	1,783,224	11
Total equity	11,527,620	77	11,790,695	77	12,043,213	77
TOTAL	\$ 14,939,803	100	\$ 15,323,638	100	\$ 15,596,957	100

- 3 -

GRAPE KING BIO LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	For the Three Months Ended March 31			
	2025		2024	
	Amount	%	Amount	%
NET REVENUE (Notes 23 and 31)	\$ 2,252,295	100	\$ 2,347,519	100
COST OF GOODS SOLD (Notes 11 and 24)	<u>(602,127)</u>	<u>(27)</u>	<u>(590,635)</u>	<u>(25)</u>
GROSS PROFIT	1,650,168	73	1,756,884	75
REALIZED GAIN (LOSS) ON TRANSACTIONS WITH ASSOCIATE	<u>(348)</u>	<u>-</u>	<u>839</u>	<u>-</u>
ADJUSTED GROSS PROFIT	<u>1,649,820</u>	<u>73</u>	<u>1,757,723</u>	<u>75</u>
OPERATING EXPENSES (Notes 21, 24 and 31)				
Selling and marketing	(1,064,144)	(47)	(1,105,686)	(47)
General and administrative	(150,451)	(7)	(154,361)	(6)
Research and development	<u>(59,119)</u>	<u>(2)</u>	<u>(61,345)</u>	<u>(3)</u>
Total operating expenses	<u>(1,273,714)</u>	<u>(56)</u>	<u>(1,321,392)</u>	<u>(56)</u>
INCOME FROM OPERATIONS	<u>376,106</u>	<u>17</u>	<u>436,331</u>	<u>19</u>
NON-OPERATING INCOME AND EXPENSES (Notes 13, 24 and 31)				
Interest income	9,560	1	12,947	1
Other income	19,008	1	20,481	1
Other gains and losses	1,335	-	7,521	-
Finance costs	(1,104)	-	(740)	-
Share of profit or loss of associate	<u>8,757</u>	<u>-</u>	<u>8,690</u>	<u>-</u>
Total non-operating income	<u>37,556</u>	<u>2</u>	<u>48,899</u>	<u>2</u>
PROFIT BEFORE INCOME TAX	413,662	19	485,230	21
INCOME TAX EXPENSE (Note 25)	<u>(85,186)</u>	<u>(4)</u>	<u>(96,394)</u>	<u>(4)</u>
NET PROFIT FOR THE PERIOD	<u>328,476</u>	<u>15</u>	<u>388,836</u>	<u>17</u>
OTHER COMPREHENSIVE INCOME (Note 22)				
Items that will not be reclassified subsequently to profit or loss:				
Unrealized gain on investments in equity instruments at fair value through other comprehensive income	-	-	2	-

(Continued)

GRAPE KING BIO LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	For the Three Months Ended March 31			
	2025		2024	
	Amount	%	Amount	%
Items that may be reclassified subsequently to profit or loss:				
Exchange differences on translating the financial statements of foreign operations	\$ 24,338	1	\$ 21,292	1
Exchange differences on translating the financial statements of foreign operations of associate	<u>1,880</u>	<u>-</u>	<u>897</u>	<u>-</u>
Other comprehensive income for the period, net of income tax	<u>26,218</u>	<u>1</u>	<u>22,191</u>	<u>1</u>
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	<u>\$ 354,694</u>	<u>16</u>	<u>\$ 411,027</u>	<u>18</u>
NET PROFIT ATTRIBUTABLE TO:				
Owners of the Company	\$ 207,647	9	\$ 257,881	11
Non-controlling interests	<u>120,829</u>	<u>6</u>	<u>130,955</u>	<u>6</u>
	<u>\$ 328,476</u>	<u>15</u>	<u>\$ 388,836</u>	<u>17</u>
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO:				
Owners of the Company	\$ 233,224	10	\$ 279,439	12
Non-controlling interests	<u>121,470</u>	<u>6</u>	<u>131,588</u>	<u>6</u>
	<u>\$ 354,694</u>	<u>16</u>	<u>\$ 411,027</u>	<u>18</u>
EARNINGS PER SHARE (Note 26)				
Basic earnings per share	<u>\$ 1.40</u>		<u>\$ 1.74</u>	
Diluted earnings per share	<u>\$ 1.40</u>		<u>\$ 1.73</u>	

The accompanying notes are an integral part of the consolidated financial statements.

(Concluded)

GRAPE KING BIO LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (In Thousands of New Taiwan Dollars)

	Equity Attributable to Owners of the Company										Total Equity
	Share Capital - Ordinary Shares						Others		Statements of Total	Non-controlling Interests	
							Exchange Differences on Translating the Financial Statements of Foreign Operations	Unrealized Gain (Loss) on Financial Assets at Fair Value Through Other Comprehensive Income			
	Number of Shares (In Thousands)	Amount	Capital Surplus	Legal Reserve	Retained Earnings Special Reserve	Unappropriated Earnings					
BALANCE AT JANUARY 1, 2024	148,137	\$ 1,481,374	\$ 2,876,346	\$ 1,474,160	\$ 70,828	\$ 4,155,148	\$ (79,665)	\$ 108	\$ 9,978,299	\$ 1,651,636	\$ 11,629,935
Other changes in capital surplus	-	-	2,251	-	-	-	-	-	2,251	-	2,251
Net profit for the three months ended March 31, 2024	-	-	-	-	-	257,881	-	-	257,881	130,955	388,836
Other comprehensive income for the three months ended March 31, 2024, net of income tax	-	-	-	-	-	-	21,556	2	21,558	633	22,191
Total comprehensive income for the three months ended March 31, 2024	-	-	-	-	-	257,881	21,556	2	279,439	131,588	411,027
BALANCE AT MARCH 31, 2024	148,137	\$ 1,481,374	\$ 2,878,597	\$ 1,474,160	\$ 70,828	\$ 4,413,029	\$ (58,109)	\$ 110	\$ 10,259,989	\$ 1,783,224	\$ 12,043,213
BALANCE AT JANUARY 1, 2025	148,137	\$ 1,481,374	\$ 2,878,597	\$ 1,678,017	\$ 47,543	\$ 4,004,929	\$ (34,761)	\$ -	\$ 10,055,699	\$ 1,734,996	\$ 11,790,695
Cash dividends	-	-	-	-	-	(622,177)	-	-	(622,177)	-	(622,177)
Net profit for the three months ended March 31, 2025	-	-	-	-	-	207,647	-	-	207,647	120,829	328,476
Other comprehensive income for the three months ended March 31, 2025, net of income tax	-	-	-	-	-	-	25,577	-	25,577	641	26,218
Total comprehensive income for the three months ended March 31, 2025	-	-	-	-	-	207,647	25,577	-	233,224	121,470	354,694
Non-controlling interests increased	-	-	-	-	-	-	-	-	-	4,408	4,408
BALANCE AT MARCH 31, 2025	148,137	\$ 1,481,374	\$ 2,878,597	\$ 1,678,017	\$ 47,543	\$ 3,590,399	\$ (9,184)	\$ -	\$ 9,666,746	\$ 1,860,874	\$ 11,527,620

The accompanying notes are an integral part of the consolidated financial statements.

GRAPE KING BIO LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands of New Taiwan Dollars)

	For the Three Months Ended March 31	
	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES		
Income before income tax	\$ 413,662	\$ 485,230
Adjustments for:		
Depreciation expenses	127,272	112,056
Amortization expenses	10,188	9,333
Net gain on financial assets at fair value through profit or loss	(154)	(211)
Finance costs	1,104	740
Interest income	(9,560)	(12,947)
Share of profit of associate	(8,757)	(8,690)
Gain on disposal of property, plant and equipment	(145)	(408)
Loss on inventories on retirement and write-down	-	(1,134)
Unrealized (realized) loss (profit) of sales	348	(839)
Unrealized gain on foreign currency exchange	(1,052)	(5,770)
Gain on modification of lease agreements	-	(1,179)
Changes in operating assets and liabilities		
Notes and accounts receivable, net	(18,507)	(36,842)
Accounts receivable from related parties	(1,378)	(7,405)
Other receivables	(601)	190
Other receivables from related parties	(10)	(12)
Inventories	(17,410)	(29,361)
Other current assets	2,423	2,441
Contract liabilities	(55,064)	(11,444)
Notes and accounts payable	7,658	16,904
Accounts payable to related parties	4,038	(1,915)
Other payables	(436,869)	(349,906)
Other payables to related parties	7,032	(38,022)
Other current liabilities	(6,725)	(11,515)
Net defined benefit liabilities	(1,215)	(480)
Cash generated from operations	16,278	108,814
Interest received	7,188	19,607
Interest paid	(9)	(9)
Income tax paid	(10,076)	(15,191)
Net cash generated from operating activities	13,381	113,221
CASH FLOWS FROM INVESTING ACTIVITIES		
Proceeds from redemption of financial assets at amortized cost	3,720	24,564
Proceeds from sale of financial assets at fair value through profit or loss	-	30,074
Acquisition of property, plant and equipment	(90,837)	(146,614)
Proceeds from disposal of property, plant and equipment	145	505
Increase in refundable deposits	(7,860)	(943)
Decrease in refundable deposits	236	367

(Continued)

GRAPE KING BIO LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands of New Taiwan Dollars)

	For the Three Months Ended March 31	
	2025	2024
Acquisition of intangible assets	\$ (4,392)	\$ (3,939)
Decrease (increase) in other non-current assets	<u>685</u>	<u>(534)</u>
Net cash used in investing activities	<u>(98,303)</u>	<u>(96,520)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Increase in guarantee deposits received	1,814	3,135
Refund of guarantee deposits received	(107)	(1,293)
Payment for the principal portion of lease liabilities	(15,654)	(13,563)
Dividends paid to owners of the Company	(399,971)	-
Changes in non-controlling interests	4,408	-
Proceeds from issuance of ordinary shares	<u>-</u>	<u>2,251</u>
Net cash used in financing activities	<u>(409,510)</u>	<u>(9,470)</u>
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	<u>13,289</u>	<u>15,326</u>
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(481,143)	22,557
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	<u>4,342,605</u>	<u>4,818,703</u>
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	<u>\$ 3,861,462</u>	<u>\$ 4,841,260</u>

The accompanying notes are an integral part of the consolidated financial statements.

(Concluded)

GRAPE KING BIO LTD. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024 (Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

1. GENERAL INFORMATION

Grape King Bio Ltd. (the “Company”) was incorporated as a listed company limited by shares under the provisions of the Company Act, the Securities and Exchange Act and other related regulations of the Republic of China (“ROC”). In April 1971, the Company was officially registered as Grape King Food Limited and started its operation. In 1979, the Company merged with China Fuso Seiko Pharmaceutical Industries Ltd. and was renamed as Grape King Inc. In 1981, the Company further merged with Head Fancy Cosmetics Co. Ltd. The Company’s shares are listed and publicly traded on the Taiwan Stock Exchange (TWSE) since December 1982. In the annual shareholders’ meeting held on June 12, 2002, the Company resolved to change its name to Grape King Bio Ltd. The Company is engaged in the production and sales of pharmaceutical preparation, patent medicine, liquid tonic, drink, healthy food, etc. The Company’s registered office and main business location is at No. 402, Sec. 2, Jinling Rd., Pingzhen Dist., Taoyuan City 324, Taiwan, Republic of China.

The consolidated financial statements are presented in the Company’s functional currency, the New Taiwan dollar.

2. APPROVAL OF CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial statements were approved by the Company’s Board of Directors and issued on May 9, 2025.

3. APPLICATION OF NEW, AMENDED AND REVISED STANDARDS AND INTERPRETATIONS

- a. The IFRS Accounting Standards endorsed by the FSC for application starting from 2026

New, Amended and Revised Standards and Interpretations	Effective Date Announced by IASB
Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments” - the amendments to the application guidance of classification of financial assets	January 1, 2026 (Note 1)

Note 1: An entity shall apply those amendments for annual reporting periods beginning on or after January 1, 2026. It is permitted to apply these amendments for an earlier period beginning on January 1, 2025.

An entity shall apply the amendments retrospectively but is not required to restate prior periods. The effect of initially applying the amendments shall be recognized as an adjustment to the opening balance at the date of initial application. An entity may restate prior periods if, and only if, it is possible to do so without the use of hindsight.

As of the date the consolidated financial statements were authorized for issue, the Group is continuously assessing the possible impact of the application of the amendments on the Group’s financial position and financial performance.

- b. The IFRS Accounting Standards in issue but not yet endorsed and issued into effect by the FSC

New, Amended and Revised Standards and Interpretations	Effective Date Announced by IASB (Note 1)
Annual Improvements to IFRS Accounting Standards - Volume 11	January 1, 2026
Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments” - the amendments to the application guidance of derecognition of financial liabilities	January 1, 2026
Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”	January 1, 2026
Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets between an Investor and its Associate or Joint Venture”	To be determined by IASB
IFRS 17 “Insurance Contracts”	January 1, 2023
Amendments to IFRS 17	January 1, 2023
Amendments to IFRS 17 “Initial Application of IFRS 9 and IFRS 17 - Comparative Information”	January 1, 2023
IFRS 18 “Presentation and Disclosures in Financial Statements”	January 1, 2027
IFRS 19 “Subsidiaries without Public Accountability: Disclosures”	January 1, 2027

Note 1: Unless stated otherwise, the above IFRSs are effective for annual reporting periods beginning on or after their respective effective dates.

As of the date the consolidated financial statements were authorized for issue, the Group is continuously assessing the possible impact of the application of other standards and interpretations on the Group’s financial position and financial performance and will disclose the relevant impact when the assessment is completed.

4. SUMMARY OF MATERIAL ACCOUNTING POLICY INFORMATION

- a. Statement of compliance

These interim consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and IAS 34 “Interim Financial Reporting” as endorsed and issued into effect by the FSC. Disclosure information included in these interim consolidated financial statements is less than the disclosure information required in a complete set of annual consolidated financial statements.

- b. Basis of preparation

The consolidated financial statements have been prepared on the historical cost basis except for financial instruments which are measured at fair value, and net defined benefit assets (liabilities) which are measured at the present value of the defined benefit obligation less the fair value of plan assets.

The fair value measurements, which are grouped into Levels 1 to 3 based on the degree to which the fair value measurement inputs are observable and based on the significance of the inputs to the fair value measurement in its entirety, are described as follows:

- 1) Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;
- 2) Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for an asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- 3) Level 3 inputs are unobservable inputs for an asset or liability.

c. Basis of consolidation

The consolidated financial statements incorporate the financial statements of the Company and the entities controlled by the Company (i.e., its subsidiaries).

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by the Group.

All intra-group transactions, balances, income and expenses are eliminated in full upon consolidation. Total comprehensive income of subsidiaries is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

See Note 12, Tables 4 and 5 for detailed information on subsidiaries (including percentages of ownership and main businesses).

d. Other material accounting policies

Except for the following, refer to the consolidated financial statements for the year ended December 31, 2024.

1) Retirement benefits

Pension cost for an interim period is calculated on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior financial year, adjusted for significant market fluctuations since that time and for significant plan amendments, settlements, or other significant one-off events.

2) Income tax expense

Income tax expense represents the sum of the tax currently payable and deferred tax. Interim period income taxes are assessed on an annual basis and calculated by applying to an interim period's pre-tax income the tax rate that would be applicable to expected total annual earnings.

5. MATERIAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

Refer to Note 5 to the statements of critical accounting judgments and key sources of estimation uncertainty to the consolidated financial statements for the year ended December 31, 2024.

6. CASH AND CASH EQUIVALENTS

	March 31, 2025	December 31, 2024	March 31, 2024
Cash on hand	\$ 2,914	\$ 1,921	\$ 2,897
Checking accounts and demand deposits	1,836,255	2,071,109	1,873,636
Cash equivalents (investments with original maturities of 3 months or less)			
Repurchase agreements collateralized by commercial paper	1,082,701	816,469	1,830,912
Repurchase agreements collateralized by bonds	416,348	933,435	1,116,215
Time deposits	523,244	519,671	17,600
	<u>\$ 3,861,462</u>	<u>\$ 4,342,605</u>	<u>\$ 4,841,260</u>

7. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

	March 31, 2025	December 31, 2024	March 31, 2024
Financial assets at fair value through profit or loss (FVTPL) - current			
Financial assets mandatorily classified as at FVTPL			
Non-derivative financial assets			
- Mutual funds	\$ 40,749	\$ 40,595	\$ 50,199

Financial assets at fair value through profit or loss were not pledged.

8. FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

	March 31, 2025	December 31, 2024	March 31, 2024
Non-current - investments in equity instruments at FVTOCI			
Unlisted shares			
Hsin Tung Yang Co., Ltd.	\$ -	\$ -	\$ 130

The Company acquired ordinary shares of Hsin Tung Yang Co., Ltd. for medium to long-term strategic purposes. Accordingly, the management elected to designate these investments in equity instruments as at FVTOCI as they believe that recognizing short-term fluctuations in these investments' fair value in profit or loss would not be consistent with the Company's strategy of holding these investments for long-term purposes.

In July 2024, the Company sold its ordinary shares of Hsin Tung Yang Co., Ltd. for \$30 thousand, and the unrealized gain on financial assets at FVTOCI of \$10 thousand was transferred to unappropriated earnings.

Financial assets at fair value through other comprehensive income were not pledged.

9. FINANCIAL ASSETS AT AMORTIZED COST

	March 31, 2025	December 31, 2024	March 31, 2024
<u>Current</u>			
Time deposits with original maturities of more than 3 months	\$ 49,328	\$ 48,813	\$ 47,958
<u>Non-current</u>			
Pledged time deposits	\$ 12,813	\$ 16,533	\$ 28,520
Time deposits with original maturities of more than 3 months	91,460	89,560	-
	\$ 104,273	\$ 106,093	\$ 28,520

Refer to Note 30 for information relating to the credit risk management and impairment of investments in financial assets at amortized cost.

Refer to Note 32 for information relating to investments in financial assets at amortized cost pledged as security.

10. NOTES AND ACCOUNTS RECEIVABLE, NET AND OTHER RECEIVABLES

	March 31, 2025	December 31, 2024	March 31, 2024
<u>Notes receivable</u>			
Notes receivable - operating	\$ 11,506	\$ 13,880	\$ 9,974
<u>Accounts receivable</u>			
At amortized cost			
Gross carrying amount	224,495	203,647	225,144
Less: Loss allowance	(829)	(829)	(829)
	<u>223,666</u>	<u>202,818</u>	<u>224,315</u>
	<u>\$ 235,172</u>	<u>\$ 216,698</u>	<u>\$ 234,289</u>
<u>Other receivables</u>			
Tax refund receivable	\$ 4,099	\$ 11,892	\$ 3,751
Other receivables	22,916	19,943	15,254
Less: Loss allowance	(1,575)	(1,575)	(1,575)
	<u>\$ 25,440</u>	<u>\$ 30,260</u>	<u>\$ 17,430</u>

a. Notes and accounts receivable

Some of the Group's customers use cash (or credit card) to settle payment; other than the customers who pay by cash (or credit card), the average credit period of sales of goods was 30-135 days. The Group adopted a policy of only dealing with entities that have passed internal credit assessment and obtaining sufficient collateral, where appropriate, as a means of mitigating the risk of financial loss from default.

In order to minimize credit risk, the management of the Group has delegated a team responsible for determining credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. In addition, the Group reviews the recoverable amount of each individual trade debt at the end of the reporting period to ensure that adequate allowance is made for possible irrecoverable amounts. In this regard, the management believes the Group's credit risk was significantly reduced.

The Group measures the loss allowance for notes and accounts receivable at an amount equal to lifetime ECLs. The expected credit losses on notes and accounts receivable are estimated using a provision matrix by reference to the past default records of the debtor and an analysis of the debtor's current financial position, adjusted for general economic conditions of the industry in which the debtors operate and an assessment of both the current as well as the forecasted direction of economic conditions at the reporting date. As the Group's historical credit loss experience does not show significantly different loss patterns for different customer segments, the provision for loss allowance based on past due status is not further distinguished according to the Group's different customer base.

The movements of the loss allowance of notes and accounts receivable were as follows:

	For the Three Months Ended March 31	
	2025	2024
Balance at January 1 and March 31	<u>\$ 829</u>	<u>\$ 829</u>

Aging analysis of notes and accounts receivable (net) held by the Group was as follows:

	Neither Past Due nor Impaired	Past Due but not Impaired			Total
		Within 90 Days	91 to 180 Days	Over 180 Days	
March 31, 2025	\$ 224,131	\$ 11,041	\$ -	\$ -	\$ 235,172
December 31, 2024	204,128	12,567	3	-	216,698
March 31, 2024	220,084	14,164	41	-	234,289

Notes and accounts receivable were not pledged.

b. Other receivables

The Group measures the loss allowance for other receivables at an amount equal to actual credit losses of customers; therefore, there is no uncertain recovery in addition to the amount as follows.

The movements of the loss allowance for other receivables were as follows:

	For the Three Months Ended March 31	
	2025	2024
Balance at January 1 and March 31	<u>\$ 1,575</u>	<u>\$ 1,575</u>

11. INVENTORIES

	March 31, 2025	December 31, 2024	March 31, 2024
Finished goods	\$ 287,045	\$ 274,919	\$ 254,676
Semi-finished goods and work in progress	246,543	248,391	211,038
Raw materials	166,744	159,711	182,004
Supplies	63,539	63,922	56,931
Merchandise	<u>7,781</u>	<u>7,508</u>	<u>13,859</u>
	<u>\$ 771,652</u>	<u>\$ 754,451</u>	<u>\$ 718,508</u>

The nature of the cost of goods sold is as follows:

	For the Three Months Ended March 31	
	2025	2024
Cost of inventories sold	<u>\$ 602,127</u>	<u>\$ 590,635</u>
Loss on retirement	<u>\$ 184</u>	<u>\$ 496</u>
Loss on inventories on retirement and write-down	<u>\$ -</u>	<u>\$ (1,134)</u>
Gain from physical counts	<u>\$ (136)</u>	<u>\$ (773)</u>

Inventories were not pledged.

12. SUBSIDIARIES

a. Subsidiaries included in the consolidated financial statements

Investor	Investee	Nature of Activities	Proportion of Ownership		
			March 31, 2025	December 31, 2024	March 31, 2024
The Company	Pro-partner Ltd. (Pro-partner)	Sales	60%	60%	60%
	GRAPE KING INTERNATIONAL INVESTMENT INC. (BVI) (GKBVI)	Investment	100%	100%	100%
	Rivershine Ltd. (Rivershine)	Sales	100%	100%	100%
	MYGK BIO SDN.BHD. (MYGK BIO)	Sales	100%	-	-
GKBVI	Shanghai Grape King Enterprise Co., Ltd. (Shanghai Grape King)	Manufacturing and Sales	100%	100%	100%
	Shanghai Rivershine Ltd. (Shanghai Rivershine)	Sales	100%	100%	100%
Pro-partner	ELITE PROPARTNER HOLDINGS SDN. BHD.	Sales	100%	100%	100%
Shanghai Grape King	UVACO MY SDN. BHD.	Sales	100%	100%	100%
	Shanghai Pujun Trading Co., Ltd. (Shanghai Pujun)	Sales	51%	51%	51%
	Shanghai Puxun Supply Chain Management Co., Ltd. (Shanghai Puxun)	Supply Chain Management	67%	67%	-
	PUBAI LIMITED (PUBAI)	Sales	55%	55%	-
	Shanghai Puyou Trading Co., Ltd. (Shanghai Puyou)	Sales	10%	10%	-
	Shanghai Puguang Trading Co., Ltd. (Shanghai Puguang)	Sales	51%	-	-
	Shanghai Pujun	Sales	51%	51%	-

b. Details of subsidiaries that have material non-controlling interests

Name of Subsidiary	Principal Place of Business	Proportion of Ownership and Voting Rights Held by Non-controlling Interests		
		March 31, 2025	December 31, 2024	March 31, 2024
Pro-partner	Taiwan	40%	40%	40%

Name of Subsidiary	Profit Allocated to Non-controlling Interests		Accumulated Non-controlling Interests		
	For the Three Months Ended March 31		March 31, 2025	December 31, 2024	March 31, 2024
	2025	2024	2025	2024	2024
Pro-partner	\$ 121,544	\$ 131,040	\$ 1,816,553	\$ 1,695,278	\$ 1,749,152

Summarized financial information of the Group's subsidiary that has material non-controlling interests is set out below. The summarized financial information below represents amounts before intragroup eliminations.

Pro-partner

	March 31, 2025	December 31, 2024	March 31, 2024
Current assets	\$ 2,933,171	\$ 2,972,751	\$ 3,420,446
Non-current assets	3,483,364	3,395,719	3,440,938
Current liabilities	(1,778,521)	(2,093,333)	(2,442,822)
Non-current liabilities	(96,630)	(36,941)	(45,683)
Equity	\$ 4,541,384	\$ 4,238,196	\$ 4,372,879

(Continued)

	March 31, 2025	December 31, 2024	March 31, 2024
Equity attributable to:			
Owners of the Company	\$ 2,724,831	\$ 2,542,918	\$ 2,623,727
Non-controlling interests of Pro-partner	<u>1,816,553</u>	<u>1,695,278</u>	<u>1,749,152</u>
	<u>\$ 4,541,384</u>	<u>\$ 4,238,196</u>	<u>\$ 4,372,879</u> (Concluded)

	For the Three Months Ended March 31	
	2025	2024
Revenue	<u>\$ 1,678,068</u>	<u>\$ 1,782,162</u>
Net profit for the period	\$ 303,860	\$ 327,601
Other comprehensive income (loss)	<u>(672)</u>	<u>17</u>
Total comprehensive income	<u>\$ 303,188</u>	<u>\$ 327,618</u>
Profit for the period attributable to:		
Owners of the Company	\$ 182,316	\$ 196,561
Non-controlling interests of Pro-partner	<u>121,544</u>	<u>131,040</u>
	<u>\$ 303,860</u>	<u>\$ 327,601</u>
Total comprehensive income attributable to:		
Owners of the Company	\$ 181,913	\$ 196,571
Non-controlling interests of Pro-partner	<u>121,275</u>	<u>131,047</u>
	<u>\$ 303,188</u>	<u>\$ 327,618</u>
Net cash (outflow) inflow from:		
Operating activities	\$ (3,964)	\$ 32,921
Investing activities	(31,840)	22,852
Financing activities	<u>(8,199)</u>	<u>(6,588)</u>
Net cash (outflow) inflow	<u>\$ (44,003)</u>	<u>\$ 49,185</u>

13. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD

	March 31, 2025	December 31, 2024	March 31, 2024
<u>Associates that are not individually material</u>			
GK BIO INTERNATIONAL SDN. BHD.	\$ 87,933	\$ 77,601	\$ 61,446
Shanghai Xinquan Biotechnology Co., Ltd.	<u>9,235</u>	<u>9,086</u>	<u>9,080</u>
	<u>\$ 97,168</u>	<u>\$ 86,687</u>	<u>\$ 70,526</u>

Aggregate information of associates that are not individually material:

	For the Three Months Ended March 31	
	2025	2024
The Group's share of:		
Net income	\$ 8,674	\$ 8,892
Other comprehensive income (loss)	<u>2,072</u>	<u>1,065</u>
Total comprehensive income	<u>\$ 10,746</u>	<u>\$ 9,957</u>

The Group had neither contingent liabilities nor capital commitments to the associates as of March 31, 2025 and 2024.

Investments in associates were not pledged.

14. PROPERTY, PLANT AND EQUIPMENT

	March 31, 2025	December 31, 2024	March 31, 2024
Assets used by the Group	<u>\$ 7,687,383</u>	<u>\$ 7,699,215</u>	<u>\$ 7,564,763</u>

a. Assets used by the Group

	For the Three Months Ended March 31, 2025					
	Balance at Beginning of Period	Additions	Disposals	Reclassification	Effects of Foreign Currency Exchange Differences	Balance at End of Period
<u>Cost</u>						
Land	\$ 2,964,746	\$ -	\$ -	\$ -	\$ -	\$ 2,964,746
Land improvements	3,264	-	-	-	-	3,264
Buildings	5,315,654	969	(2)	14,395	9,889	5,340,905
Machinery and equipment	2,340,475	15,644	(14,122)	11,547	6,732	2,360,276
Transportation equipment	28,985	160	-	-	73	29,218
Leasehold improvements	108,511	-	-	-	53	108,564
Other equipment	453,294	3,719	(9,390)	108	523	448,254
Construction in progress	162,139	59,928	-	(18,596)	6	203,477
	<u>11,377,068</u>	<u>\$ 80,420</u>	<u>\$ (23,514)</u>	<u>\$ 7,454</u>	<u>\$ 17,276</u>	<u>11,458,704</u>
<u>Accumulated depreciation</u>						
Land	-	\$ -	\$ -	\$ -	\$ -	-
Land improvements	2,673	35	-	-	-	2,708
Buildings	1,664,833	52,721	(2)	-	3,959	1,721,511
Machinery and equipment	1,517,309	44,563	(14,122)	-	4,477	1,552,227
Transportation equipment	17,848	656	-	-	74	18,578
Leasehold improvements	94,187	1,589	-	-	31	95,807
Other equipment	381,003	8,412	(9,390)	-	465	380,490
	<u>3,677,853</u>	<u>\$ 107,976</u>	<u>\$ (23,514)</u>	<u>\$ -</u>	<u>\$ 9,006</u>	<u>3,771,321</u>
Carrying amount at March 31, 2024	<u>\$ 7,699,215</u>					<u>\$ 7,687,383</u>

For the Three Months Ended March 31, 2024

	Balance at Beginning of Period	Additions	Disposals	Reclassification	Effects of Foreign Currency Exchange Differences	Balance at End of Period
<u>Cost</u>						
Land	\$ 2,964,746	\$ -	\$ -	\$ -	\$ -	\$ 2,964,746
Land improvements	3,264	-	-	-	-	3,264
Buildings	4,923,098	2,784	-	-	8,403	4,934,285
Machinery and equipment	1,971,127	17,846	-	1,808	5,354	1,996,135
Transportation equipment	22,359	-	(427)	-	76	22,008
Leasehold improvements	108,428	-	-	-	45	108,473
Other equipment	437,968	3,487	(540)	1,455	439	442,809
Construction in progress	386,261	92,720	-	(4,420)	105	474,666
	<u>10,817,251</u>	<u>\$ 116,837</u>	<u>\$ (967)</u>	<u>\$ (1,157)</u>	<u>\$ 14,422</u>	<u>10,946,386</u>
<u>Accumulated depreciation</u>						
Land	-	\$ -	\$ -	\$ -	\$ -	-
Land improvements	2,510	57	-	-	-	2,567
Buildings	1,465,923	48,421	-	-	3,139	1,517,483
Machinery and equipment	1,363,529	33,914	-	-	3,358	1,400,801
Transportation equipment	18,528	297	(330)	-	68	18,563
Leasehold improvements	81,252	3,222	-	-	26	84,500
Other equipment	346,827	11,043	(540)	-	379	357,709
	<u>3,278,569</u>	<u>\$ 96,954</u>	<u>\$ (870)</u>	<u>\$ -</u>	<u>\$ 6,970</u>	<u>3,381,623</u>
Carrying amount at March 31, 2024	<u>\$ 7,538,682</u>					<u>\$ 7,564,763</u>

The significant parts of the Group's buildings include main plants, air conditioning, electrical and wastewater treatment equipment and decoration, and the related depreciation is calculated based on the economic lives as below:

Significant Part of Buildings	Estimated Economic Lives
Main plant	30 to 60 years
Air conditioning and electrical	5 to 22 years
Wastewater treatment equipment	10 to 15 years
Decoration	15 years

No impairment assessment was performed for the three months ended March 31, 2025 and 2024 as there was no indication of impairment.

Property, plant and equipment pledged as collateral for bank borrowings are set out in Note 32.

15. LEASE ARRANGEMENTS

a. Right-of-use assets

	March 31, 2025	December 31, 2024	March 31, 2024
<u>Carrying amounts</u>			
Land	\$ 79,779	\$ 80,081	\$ 82,532
Buildings	163,524	89,241	118,310
Transportation equipment	25,264	16,653	10,531
Other equipment	<u>304</u>	<u>339</u>	<u>781</u>
	<u>\$ 268,871</u>	<u>\$ 186,314</u>	<u>\$ 212,154</u>

	For the Three Months Ended March 31	
	2025	2024
Additions to right-of-use assets	<u>\$ 98,909</u>	<u>\$ 4,254</u>
Depreciation charge for right-of-use assets		
Land	\$ 1,000	\$ 970
Buildings	13,792	10,712
Transportation equipment	2,291	1,272
Other equipment	<u>35</u>	<u>174</u>
	<u>\$ 17,118</u>	<u>\$ 13,128</u>

Except for the aforementioned additions and recognized depreciation, the Group did not have significant sublease or impairment of right-of-use assets during the three months ended March 31, 2025 and 2024.

b. Lease liabilities

	March 31, 2025	December 31, 2024	March 31, 2024
<u>Carrying amounts</u>			
Current	<u>\$ 72,027</u>	<u>\$ 53,948</u>	<u>\$ 56,813</u>
Non-current	<u>\$ 172,801</u>	<u>\$ 106,963</u>	<u>\$ 128,986</u>

Range of discount rate for lease liabilities was as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Land	1.02%-1.84%	1.02%-1.84%	1.02%-1.84%
Buildings	1.02%-2.07%	1.02%-1.875%	1.02%-1.80%
Transportation equipment	1.02%-3.14%	1.02%-3.14%	1.02%-3.14%
Other equipment	1.02%-1.84%	1.02%-1.875%	1.00%-1.84%

c. Material leasing activities and terms

The Group leases certain land, buildings and transportation equipment with lease terms of 3 to 50 years. Lease payments for the lease contract of land will be adjusted on the basis of changes in announced land value prices. The Group does not have bargain purchase options to acquire the leasehold land and buildings at the end of the lease terms.

The Group also leases certain transportation equipment under finance leases. The lease period is 3 years. Upon the expiration of the lease period, ownership of the transportation equipment will be automatically transferred to the Group. The Group's finance lease obligations are secured by the lessor's ownership of the leased assets.

d. Other lease information

	For the Three Months Ended March 31	
	2025	2024
Expenses relating to short-term and low-value asset leases	<u>\$ 4,195</u>	<u>\$ 4079</u>
Total cash outflow for leases	<u>\$ (19,849)</u>	<u>\$ (17,642)</u>

The Group leases certain land, transportation equipment and other equipment under leases which qualify as short-term leases and low-value asset leases. The Group has elected to apply the recognition exemption and thus did not recognize right-of-use assets and lease liabilities for these leases.

16. INVESTMENT PROPERTIES

	Land	Buildings	Total
<u>Cost</u>			
Balance at January 1 and March 31, 2025	<u>\$ 1,141,278</u>	<u>\$ 348,820</u>	<u>\$ 1,490,098</u>
<u>Accumulated depreciation</u>			
Balance at January 1, 2025	\$ -	\$ 86,005	\$ 86,005
Depreciation expenses	<u>-</u>	<u>2,178</u>	<u>2,178</u>
Balance at March 31, 2025	<u>\$ -</u>	<u>\$ 88,183</u>	<u>\$ 88,183</u>
Carrying amount at January 1, 2025	<u>\$ 1,141,278</u>	<u>\$ 262,815</u>	<u>\$ 1,404,093</u>
Carrying amount at March 31, 2025	<u>\$ 1,141,278</u>	<u>\$ 260,637</u>	<u>\$ 1,401,915</u>
<u>Cost</u>			
Balance at January 1 and March 31, 2024	<u>\$ 1,141,278</u>	<u>\$ 344,729</u>	<u>\$ 1,486,007</u>
<u>Accumulated depreciation</u>			
Balance at January 1, 2024	\$ -	\$ 77,633	\$ 77,633
Depreciation expenses	<u>-</u>	<u>1,974</u>	<u>1,974</u>
Balance at March 31, 2024	<u>\$ -</u>	<u>\$ 79,607</u>	<u>\$ 79,607</u>
Carrying amount at March 31, 2024	<u>\$ 1,141,278</u>	<u>\$ 265,122</u>	<u>\$ 1,406,400</u>

The investment properties were leased out for 3 to 10 years. The lease contracts contain market review clauses in the event that the lessees exercise their options to extend. The lessees do not have bargain purchase options to acquire the investment properties at the expiry of the lease periods.

The maturity analysis of lease payments receivable under operating leases of investment properties as of March 31, 2025 and December 31, 2024 and March 31, 2024 was as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Year 1	\$ 18,548	\$ 19,141	\$ 16,025
Year 2	11,996	15,890	15,628
Year 3	3,005	3,984	9,076
Year 4	1,541	1,934	2,503
Year 5	948	948	1,523
More than 5 years	<u>560</u>	<u>770</u>	<u>1,400</u>
	<u>\$ 36,598</u>	<u>\$ 42,667</u>	<u>\$ 46,155</u>

Except for depreciation recognized, the Group did not have significant addition, disposal, or impairment of investment properties during the three months ended March 31, 2025 and 2024. Investment properties are depreciated using the straight-line method over their estimated useful lives of 5 to 50 years.

Investment properties held by the Group are not measured at fair value while its fair value is disclosed. The determination of fair value was not performed by independent qualified professional valuers. The valuation was arrived at by reference to announced land value prices and market evidence of transaction prices for similar properties.

	March 31, 2025	December 31, 2024	March 31, 2024
Fair value	<u>\$ 1,953,428</u>	<u>\$ 1,930,129</u>	<u>\$ 1,839,448</u>

The investment property - land listed above includes a piece of agricultural land in the amount of NT\$5,600 thousand, which has been acquired due to a settlement of doubtful accounts by the Company but registered under the name of the Company's chairman, Mr. Tseng. The Company has obtained a guaranteed note amounting to NT\$5,600 thousand from Mr. Tseng for security purpose.

Investment properties were not pledged.

17. INTANGIBLE ASSETS

	Computer Software	Trademarks	Customer Relations	Total
<u>Cost</u>				
Balance at January 1, 2025	\$ 170,443	\$ 16,137	\$ 60,789	\$ 247,369
Additions	4,392	-	-	4,392
Disposals	(2,180)	-	-	(2,180)
Reclassification adjustments	1,350	-	-	1,350
Effects of foreign currency exchange differences	<u>101</u>	<u>2</u>	<u>1,290</u>	<u>1,393</u>
Balance at March 31, 2025	<u>\$ 174,106</u>	<u>\$ 16,139</u>	<u>\$ 62,079</u>	<u>\$ 252,324</u>

(Continued)

	Computer Software	Trademarks	Customer Relations	Total
<u>Accumulated amortization</u>				
Balance at January 1, 2025	\$ 95,332	\$ 16,094	\$ 17,223	\$ 128,649
Amortization expenses	7,124	2	3,062	10,188
Disposals	(2,180)	-	-	(2,180)
Effects of foreign currency exchange differences	<u>49</u>	<u>1</u>	<u>408</u>	<u>458</u>
Balance at March 31, 2025	<u>\$ 100,325</u>	<u>\$ 16,097</u>	<u>\$ 20,693</u>	<u>\$ 137,115</u>
Carrying amount at January 1, 2025	<u>\$ 75,111</u>	<u>\$ 43</u>	<u>\$ 43,566</u>	<u>\$ 118,720</u>
Carrying amount at March 31, 2025	<u>\$ 73,781</u>	<u>\$ 42</u>	<u>\$ 41,386</u>	<u>\$ 115,209</u>

Cost

Balance at January 1, 2024	\$ 140,222	\$ 16,135	\$ 58,739	\$ 215,096
Additions	3,939	-	-	3,939
Reclassification adjustments	2,342	-	-	2,342
Effects of foreign currency exchange differences	<u>79</u>	<u>1</u>	<u>1,100</u>	<u>1,180</u>
Balance at March 31, 2024	<u>\$ 146,582</u>	<u>\$ 16,136</u>	<u>\$ 59,839</u>	<u>\$ 222,557</u>

Accumulated amortization

Balance at January 1, 2024	\$ 69,213	\$ 15,901	\$ 4,895	\$ 90,009
Amortization expenses	6,313	57	2,963	9,333
Effects of foreign currency exchange differences	<u>34</u>	<u>1</u>	<u>120</u>	<u>155</u>
Balance at March 31, 2024	<u>\$ 75,560</u>	<u>\$ 15,959</u>	<u>\$ 7,978</u>	<u>\$ 99,497</u>
Carrying amount at March 31, 2024	<u>\$ 71,022</u>	<u>\$ 177</u>	<u>\$ 51,861</u>	<u>\$ 123,060</u>

(Concluded)

Except for the aforementioned addition, disposal and recognized amortization, the Group did not have disposal or impairment of other intangible assets during the three months ended March 31, 2025 and 2024. Intangible assets are amortized on a straight-line basis over their estimated useful lives as follows:

Computer software	3-10 years
Trademark	4-10 years
Customer Relations	5 years

	For the Three Months Ended March 31	
	2025	2024
An analysis of depreciation by function		
Operating costs	\$ 366	\$ 160
Selling and marketing expenses	1,206	1,770
General and administrative expenses	8,415	7,250
Research and development expenses	<u>201</u>	<u>153</u>
	<u>\$ 10,188</u>	<u>\$ 9,333</u>

18. OTHER ASSETS

	March 31, 2025	December 31, 2024	March 31, 2024
<u>Current assets</u>			
Prepayments for purchases	\$ 49,870	\$ 55,042	\$ 42,887
Office supplies	3,465	4,147	3,310
Other prepaid expense	15,569	13,799	13,534
Other current assets	<u>2,853</u>	<u>1,192</u>	<u>3,109</u>
	<u>\$ 71,757</u>	<u>\$ 74,180</u>	<u>\$ 62,840</u>
<u>Non-current assets</u>			
Prepayments for equipment	\$ 49,182	\$ 62,984	\$ 59,301
Net defined benefit assets	32,075	30,860	23,055
Refundable deposits	24,129	16,455	16,687
Other non-current assets	<u>4,999</u>	<u>5,684</u>	<u>5,931</u>
	<u>\$ 110,385</u>	<u>\$ 115,983</u>	<u>\$ 104,974</u>

19. OTHER LIABILITIES

	March 31, 2025	December 31, 2024	March 31, 2024
<u>Current</u>			
Other payables			
Bonus to direct sellers	\$ 718,834	\$ 1,148,132	\$ 752,668
Dividends payable	622,177	399,971	-
Bonus to employees	268,436	235,669	272,992
Salaries and incentive bonus	162,233	159,451	159,293
Bonus to directors and supervisor	86,411	74,681	86,969
Accrued VAT payable	35,586	83,446	38,569
Payables for purchases of equipment	31,691	46,725	72,386
Other accrued expenses	245,700	252,000	223,857
Others	<u>2,590</u>	<u>3,352</u>	<u>5,156</u>
	<u>\$ 2,173,658</u>	<u>\$ 2,403,427</u>	<u>\$ 1,611,890</u>
Other liabilities			
Guarantee deposits received	\$ 1,810	\$ -	\$ 2,755
Unearned rent	1,767	1,422	1,566
Other current liabilities	<u>30,870</u>	<u>37,940</u>	<u>14,619</u>
	<u>\$ 34,447</u>	<u>\$ 39,362</u>	<u>\$ 18,940</u>

(Continued)

	March 31, 2025	December 31, 2024	March 31, 2024
<u>Non-current</u>			
Guarantee deposits received	\$ 10,322	\$ 10,381	\$ 10,816
Net defined benefit liabilities	<u>-</u>	<u>-</u>	<u>192</u>
	<u>\$ 10,322</u>	<u>\$ 10,381</u>	<u>\$ 11,008</u> (Concluded)

20. PROVISIONS

	March 31, 2025	December 31, 2024	March 31, 2024
<u>Non-current</u>			
Decommissioning, restoration and rehabilitation	<u>\$ 10,297</u>	<u>\$ 9,826</u>	<u>\$ 9,760</u>

The movements of the provision for decommissioning, restoration and rehabilitation activities were as follows:

	<u>For the Three Months Ended March 31</u>	
	2025	2024
Balance at January 1	\$ 9,826	\$ 9,739
Addition during the year	451	-
Discount rate adjustment and unwinding of discount from the passage of time	<u>20</u>	<u>21</u>
Balance at March 31	<u>\$ 10,297</u>	<u>\$ 9,760</u>

The Group recognized provision for decommissioning of a factory site according to a contract.

21. RETIREMENT BENEFIT PLANS

a. Defined contribution plan

Expenses under the defined contribution plan for the three months ended March 31, 2025 and 2024 were NT\$9,667 thousand and NT\$9,183 thousand, respectively.

b. Defined benefit plans

Employee benefit expenses in respect of the Group's defined benefit retirement plans were calculated using the actuarially determined pension cost discount rate; expenses under the defined benefit plan for the three months ended March 31, 2025 and 2024 were NT\$159 thousand and NT\$108 thousand, respectively.

22. EQUITY

a. Share capital

1) Ordinary shares

	March 31, 2025	December 31, 2024	March 31, 2024
Shares authorized (in thousands of shares)	<u>180,000</u>	<u>180,000</u>	<u>180,000</u>
Shares authorized, par value \$10 (in thousands of dollars)	<u>\$ 1,800,000</u>	<u>\$ 1,800,000</u>	<u>\$ 1,800,000</u>
Shares issued and fully paid (in thousands of shares)	<u>148,137</u>	<u>148,137</u>	<u>148,137</u>
Shares issued through public issue	\$ 1,481,374	\$ 1,481,374	\$ 1,362,864
Shares issued through private placement	<u>-</u>	<u>-</u>	<u>118,510</u>
Shares issued and fully paid (in thousands of dollars)	<u>\$ 1,481,374</u>	<u>\$ 1,481,374</u>	<u>\$ 1,481,374</u>

Each share possesses one voting right and a right to receive dividends.

On January 14, 2021, the Company held the first extraordinary shareholders' meeting and a resolution was passed to increase cash capital by issuing ordinary shares through private placement with Uni-President Enterprise Co., Ltd., a strategic investor, as the subscriber. The purpose of the capital increase is to raise funds for capital expenditures, to enrich working capital and help strengthen the capital structure. On January 14, 2021, the Company resolved to offer for subscription and issued 11,851 thousand ordinary shares of the Company. The subscription price was \$170 per share, and a total of \$2,014,670 thousand in cash was received. The record date of the cash capital increase was January 19, 2021. The rights and obligations of the shareholders of the ordinary shares issued through this private placement are the same as those of the shareholders of the Company's issued ordinary shares. However, in accordance with Article 43-8 of the Securities and Exchange Act, the ordinary shares of this private placement shall not be freely transferred within three years from the date of subscription. The Company's Board of Directors, on May 13, 2024, resolved to publicly issue the privately placed common shares and applied with the Taiwan Stock Exchange for the shares to take effect on August 14, 2024.

b. Capital surplus

	March 31, 2025	December 31, 2024	March 31, 2024
May be used to offset a deficit, distributed as cash dividends, or transferred to share capital (1)			
Additional paid-in capital	\$ 2,850,440	\$ 2,850,440	\$ 2,850,440
Treasury share transactions	2,672	2,672	2,672
<u>May only be used to offset a deficit</u>			
Convertible bonds - expired share options	150	150	150
Treasury share transactions - share options	6,749	6,749	6,749
Arising from share of changes in capital surplus of associates	2,809	2,809	2,809
Other (2)	<u>15,777</u>	<u>15,777</u>	<u>15,777</u>
	<u>\$ 2,878,597</u>	<u>\$ 2,878,597</u>	<u>\$ 2,878,597</u>

1) Such capital surplus may be used to offset a deficit; in addition, when the Company has no deficit, such capital surplus may be distributed as cash dividends or transferred to share capital (limited to a certain percentage of the Company's capital surplus and to once a year).

2) Other is unclaimed dividend.

c. Retained earnings and dividends policy

The shareholders of the Company held their regular shareholders' meeting on May 30, 2024, and in that meeting, resolved the amendments to the Company's Articles of Incorporation (the "Articles"). The Company's earnings distribution or loss off-setting proposal may be proposed at the close of each half a year.

Under the dividends policy as set forth in the amended Articles, the Company's earnings distribution or loss off-setting proposal may be proposed at the close of each half a year. Where the Company has a profit at the end of each half a year, the Company shall estimate and reserve the taxes to be paid, offset losses according to regulation, estimate employees and directors' compensation, and allocate 10% as legal reserve, unless accumulated legal reserve has reached the total paid-in capital. Then, set aside or reverse a special reserve in accordance with relevant regulations. If a surplus remains, the balance combined with undistributed retained earnings from preceding periods shall be distributed according to the distribution plan proposed by the Board of Directors. If distributing in the form of cash, it shall be approved by the Board of Directors. If distributing in the form of new shares to be issue, the plan shall be submitted to the shareholders' meeting for approval.

The Company shall pay taxes and cover accumulated deficits and then make appropriate provision of approximately 10% for the legal reserve. In the case of making profit earnings at the end of business year after settlement, while the legal reserve reaches the paid-in capital of the Company, it may not make an provision anymore. The Company may make appropriate provision or reverse to special reserve for the surplus. In the event of an undistributed earnings of current year, it shall combine with accumulated undistributed earnings to apply for formulating earning distribution proposal to Board of Directors. Distribution in cash shall be determined after a resolution adopted by a majority vote at a meeting of the Board of Directors attended by two-thirds of the total number of directors; a report of such distribution shall be submitted to the shareholders' meeting. Distribution in the form of new share issuance shall be determined by a resolution at the shareholders' meeting.

According to the Company's Articles of Association before amendment, both the Company and Pro-partner Ltd. shall distribute their annual earnings, if any, in the sequence listed below:

1) Paying taxes;

2) Offsetting losses of previous years;

3) Setting aside as legal reserve 10% of the remaining profit;

4) Setting aside or reversing a special reserve in accordance with the laws and regulations; and

5) Any remaining profit together with any undistributed retained earnings shall be used by the Company's Board of Directors as the basis for proposing a distribution plan, which should be resolved in the shareholders' meeting for the distribution of dividends and bonuses to shareholders.

For the policies on the distribution of compensation of employees and remuneration of directors after the amendment, refer to compensation of employees and remuneration of directors in Note 24-h.

The Company's dividend policy shall be determined pursuant to the factors, such as the investment environment, capital requirement, domestic and overseas competition environment, current and future business development plan, as well as shareholders' interests. The distribution of shareholder dividends shall not be lower than 60% of the unappropriated earnings of the current year. However, the shareholders may resolve not to distribute dividends if the accumulated earnings were lower than 10% of the paid-in capital. Dividends can be distributed in the form of cash or shares or a combination of both cash and shares, out of which at least 10% of the total dividends distributed shall be in cash.

Appropriation of earnings to the legal reserve shall be made until the legal reserve equals the Company's paid-in capital. The legal reserve may be used to offset deficits. If the Company has no deficit and the legal reserve has exceeded 25% of the Company's paid-in capital, the excess may be transferred to capital or distributed in cash.

The appropriations of earnings for the first half of 2024 that was approved by the Board of Directors on November 11, 2024, was as follows:

	First Half of 2024
Legal reserve	<u>\$ 58,564</u>
Special reserve	<u>\$ (32,014)</u>
Cash dividends	<u>\$ 399,971</u>
Cash dividends per share (NT\$)	<u>\$ 2.7</u>

The appropriations of earnings for the second half of 2024 was as follows:

	Second Half of 2024
Legal reserve	<u>\$ 86,683</u>
Special reserve	<u>\$ (12,782)</u>
Cash dividends	<u>\$ 622,177</u>
Cash dividends per share (NT\$)	<u>\$ 4.2</u>

The appropriation of cash dividends for the second half of 2024 was approved by the Board of Directors on February 26, 2025. The other appropriations of earnings for 2024 will be approved in the shareholders' meeting on May 26, 2025 (expected).

The appropriations of earnings for 2023 that was proposed in the shareholders' meeting on May 30, 2024, was as follows:

	For the Years Ended December 31, 2023
Legal reserve	<u>\$ 145,293</u>
Special reserve	<u>\$ 8,729</u>
Cash dividends	<u>\$ 1,022,148</u>
Cash dividends per share (NT\$)	<u>\$ 6.9</u>

Pro-Partner's appropriations of earnings for 2024 and 2023 that were approved in the shareholders' meetings on April 22, 2025 and April 16, 2024, respectively, were as follows:

	For the Years Ended December 31	
	2024	2023
Legal reserve	\$ 181,268	\$ 172,124
Cash dividends	\$ 1,701,411	\$ 1,619,120
Cash dividends per share (NT\$)	\$ 96.67	\$ 92.00

d. Other equity items

1) Exchange differences on translating the financial statements of foreign operations

	For the Three Months Ended March 31	
	2025	2024
Balance at beginning of period	\$ (34,761)	\$ (79,665)
Recognized for the period		
Exchange differences on translating the financial statements of foreign operations	<u>25,577</u>	<u>21,556</u>
Balance at end of period	<u>\$ (9,184)</u>	<u>\$ (58,109)</u>

2) Unrealized gain on financial assets at FVTOCI

	For the Three Months Ended March 31	
	2025	2024
Balance at beginning of period	\$ -	\$ 108
Recognized for the period		
Unrealized loss - equity instruments	<u>-</u>	<u>2</u>
Other comprehensive loss for the period	<u>-</u>	<u>2</u>
Balance at end of period	<u>\$ -</u>	<u>\$ 110</u>

e. Non-controlling interests

	For the Three Months Ended March 31	
	2025	2024
Balance at beginning of period	\$ 1,734,996	\$ 1,651,636
Profit for the period	120,829	130,955
Other comprehensive income (loss) for the year		
Exchange differences on translating the financial statements of foreign operations	641	633
Acquisition of increased non-controlling interests in subsidiaries	<u>4,408</u>	<u>-</u>
Balance at end of period	<u>\$ 1,860,874</u>	<u>\$ 1,783,224</u>

23. REVENUE

	For the Three Months Ended March 31	
	2025	2024
Revenue from contracts with customers		
Revenue from the sale of goods	\$ 2,002,324	\$ 2,140,918
Revenue from the rendering of services	<u>249,971</u>	<u>206,601</u>
	<u>\$ 2,252,295</u>	<u>\$ 2,347,519</u>

a. Disaggregation of revenue

1) Type of goods or services and timing of revenue recognition:

For the three months ended March 31, 2025

	Reportable Segments				
	MLM	Distribution	ODM/OEM	Sales Channel	Total
<u>Type of goods or services</u>					
Sale of goods	\$ 1,678,068	\$ 160,031	\$ -	\$ 164,225	\$ 2,002,324
Rendering of services	<u>-</u>	<u>-</u>	<u>249,971</u>	<u>-</u>	<u>249,971</u>
	<u>\$ 1,678,068</u>	<u>\$ 160,031</u>	<u>\$ 249,971</u>	<u>\$ 164,225</u>	<u>\$ 2,252,295</u>

Timing of revenue recognition

Satisfied at a point in time	<u>\$ 1,678,068</u>	<u>\$ 160,031</u>	<u>\$ 249,971</u>	<u>\$ 164,225</u>	<u>\$ 2,252,295</u>
------------------------------	---------------------	-------------------	-------------------	-------------------	---------------------

For the three months ended March 31, 2024

	Reportable Segments				
	MLM	Distribution	ODM/OEM	Sales Channel	Total
<u>Type of goods or services</u>					
Sale of goods	\$ 1,782,162	\$ 187,661	\$ -	\$ 171,095	\$ 2,140,918
Rendering of services	<u>-</u>	<u>-</u>	<u>206,601</u>	<u>-</u>	<u>206,601</u>
	<u>\$ 1,782,162</u>	<u>\$ 187,661</u>	<u>\$ 206,601</u>	<u>\$ 171,095</u>	<u>\$ 2,347,519</u>

Timing of revenue recognition

Satisfied at a point in time	<u>\$ 1,782,162</u>	<u>\$ 187,661</u>	<u>\$ 206,601</u>	<u>\$ 171,095</u>	<u>\$ 2,347,519</u>
------------------------------	---------------------	-------------------	-------------------	-------------------	---------------------

2) Type of goods

	For the Three Months Ended March 31	
	2025	2024
<u>Type of goods</u>		
Health food	\$ 1,671,516	\$ 1,791,643
ODM/OEM	249,971	206,601
Sales Channel (Note 1)	164,225	171,095
Cosmetics	107,908	83,536
Beverage	52,494	82,631
Others (Note 2)	<u>6,181</u>	<u>12,013</u>
	<u>\$ 2,252,295</u>	<u>\$ 2,347,519</u>

Note 1: Sales channel is the Group's business of selling products from other companies for the purpose of building its own brand channels.

Note 2: Others include general food and pet food.

b. Contract balances

	March 31, 2025	December 31, 2024	March 31, 2024	January 1, 2024
Notes and accounts receivable, net	<u>\$ 235,172</u>	<u>\$ 216,698</u>	<u>\$ 234,289</u>	<u>\$ 197,231</u>
Accounts receivable from related parties	<u>\$ 89,607</u>	<u>\$ 88,123</u>	<u>\$ 102,139</u>	<u>\$ 93,580</u>
Contract liabilities - current				
Sale of goods	\$ 40,054	\$ 84,425	\$ 63,808	\$ 89,325
Rendering of services	<u>46,934</u>	<u>57,627</u>	<u>74,432</u>	<u>60,359</u>
	<u>\$ 86,988</u>	<u>\$ 142,052</u>	<u>\$ 138,240</u>	<u>\$ 149,684</u>

The changes in the balance of contract liabilities primarily resulted from the timing difference between the Group's satisfaction of performance obligations and the respective customer's payment.

Revenue in the current year that was recognized from the contract liability balance at the beginning of the year was summarized as follows:

	For the Three Months Ended March 31	
	2025	2024
From contract liabilities at the start of the year		
Revenue from the sale of goods	\$ 84,281	\$ 89,422
Revenue from contracts with customers	<u>43,089</u>	<u>49,941</u>
	<u>\$ 127,370</u>	<u>\$ 139,363</u>

24. NET PROFIT (LOSS) FROM CONTINUING OPERATIONS

a. Interest income

	For the Three Months Ended March 31	
	2025	2024
Financial assets at amortized cost	<u>\$ 9,560</u>	<u>\$ 12,947</u>

b. Other income

	For the Three Months Ended March 31	
	2025	2024
Rental income	\$ 7,914	\$ 7,102
Others	<u>11,094</u>	<u>13,379</u>
	<u>\$ 19,008</u>	<u>\$ 20,481</u>

c. Other gains and losses

	For the Three Months Ended March 31	
	2025	2024
Fair value changes of financial assets and financial liabilities		
Financial assets mandatorily classified as at FVTPL	\$ 154	\$ 211
Net foreign exchange gain	1,045	5,717
Gain on modification of lease agreements	-	1,179
Gain on disposal of property, plant and equipment	145	408
Others	<u>(9)</u>	<u>6</u>
	<u>\$ 1,335</u>	<u>\$ 7,521</u>

d. Finance costs

	For the Three Months Ended March 31	
	2025	2024
Interest on lease liabilities	\$ 1,075	\$ 710
Imputed interest on deposit	9	9
Unwinding of discount on provisions	<u>20</u>	<u>21</u>
	<u>\$ 1,104</u>	<u>\$ 740</u>

e. Depreciation and amortization

	For the Three Months Ended March 31	
	2025	2024
An analysis of depreciation by function		
Operating costs	\$ 74,882	\$ 61,198
Operating expenses	<u>52,390</u>	<u>50,858</u>
	<u>\$ 127,272</u>	<u>\$ 112,056</u>
An analysis of amortization by function		
Operating costs	\$ 366	\$ 160
Operating expenses	<u>9,822</u>	<u>9,173</u>
	<u>\$ 10,188</u>	<u>\$ 9,333</u>

Refer to Note 17 for information relating to the line item in which any amortization of intangible assets is included.

f. Operating expenses directly related to investment properties

	For the Three Months Ended March 31	
	2025	2024
Direct operating expenses from investment properties generating rental income	\$ 1,076	\$ 1,076
Direct operating expenses from investment properties not generating rental income	<u>1,102</u>	<u>897</u>
	<u>\$ 2,178</u>	<u>\$ 1,973</u>

g. Employee benefits expense

	For the Three Months Ended March 31	
	2025	2024
Short-term benefits	\$ 297,878	\$ 300,818
Post-employment benefits (Note 21)		
Defined contribution plan	9,677	9,183
Defined benefit plans	<u>159</u>	<u>108</u>
	<u>9,836</u>	<u>9,291</u>
Other employee benefits	<u>7,336</u>	<u>7,530</u>
Total employee benefits expense	<u>\$ 315,050</u>	<u>\$ 317,639</u>
An analysis of employee benefits expense by function		
Operating costs	\$ 68,138	\$ 65,747
Operating expenses	<u>246,912</u>	<u>251,892</u>
	<u>\$ 315,050</u>	<u>\$ 317,639</u>

h. Compensation of employees and remuneration of directors

According to the Company's Articles of Incorporation, 6%-8% of profit of the current year is distributable as compensation of employees and no higher than 2% of profit of the current year is distributable as remuneration of directors. In accordance with the amendments to the Securities and Exchange Act in August 2024, the Company expects to resolve the amendments to the Company's Articles at their 2025 shareholders' meeting. The amendments explicitly stipulate that no less than 30% of the compensation of employees shall be distributed to non-executive employees. The compensation of employees (including non-executive employees) and the remuneration of directors for the three months ended March 31, 2025 and 2024 are as follows:

Accrual rate

	For the Three Months Ended March 31	
	2025	2024
Compensation of employees	8%	8%
Remuneration of directors	2%	2%

Amount

	For the Three Months Ended March 31	
	2025	2024
Compensation of employees	\$ 19,096	\$ 23,994
Remuneration of directors	4,774	5,998

If there is a change in the amounts after the annual consolidated financial statements are authorized for issue, the differences are recorded as a change in the accounting estimate.

The appropriations of earnings for the compensation of employees and remuneration of directors for 2024 and 2023 that were resolved by the Company's Board of Directors on February 26, 2025 and February 26, 2024, respectively, are as shown below:

	For the Years Ended December 31	
	2024	2023
	Cash	Cash
Compensation of employees	\$ 132,782	\$ 136,129
Remuneration of directors	33,196	34,032

There is no difference between the actual amounts of compensation of employees and remuneration of directors paid and the amounts recognized in the consolidated financial statements for the years ended December 31, 2024 and 2023.

Information on the compensation of employees and remuneration of directors resolved by the Company's Board of Directors is available at the Market Observation Post System website of the Taiwan Stock Exchange.

25. INCOME TAXES

a. Income tax recognized in profit or loss

Major components of income tax expense are as follows:

	For the Three Months Ended March 31	
	2025	2024
Current tax		
In respect of the current period	\$ 82,040	\$ 94,807
Deferred tax		
In respect of the current period	<u>3,146</u>	<u>1,587</u>
Income tax expense recognized in profit or loss	<u>\$ 85,186</u>	<u>\$ 96,394</u>

b. Income tax assessments

The tax authorities have assessed the income tax returns of the Company through 2022.

26. EARNINGS PER SHARE

Unit: NT\$ Per Share

	For the Three Months Ended March 31	
	2025	2024
Basic earnings per share	\$ 1.40	\$ 1.74
Diluted earnings per share	\$ 1.40	\$ 1.73

The earnings and weighted average number of ordinary shares outstanding used in the computation of earnings per share are as follows:

Net profit for the period

	For the Three Months Ended March 31	
	2025	2024
Earnings used in the computation of basic and diluted earnings per share	\$ 207,647	\$ 257,881

Weighted average number of ordinary shares outstanding

Unit: In Thousands of Shares

	For the Three Months Ended March 31	
	2025	2024
Weighted average number of ordinary shares used in the computation of basic earnings per share	148,137	148,137
Effect of potentially dilutive ordinary shares		
Compensation of employees	696	702
Weighted average number of ordinary shares used in the computation of diluted earnings per share	148,833	148,839

If the Company offered to settle the compensation or bonuses paid to employees in cash or shares, the Company assumed that the entire amount of the compensation or bonuses will be settled in shares, and the resulting potential shares were included in the weighted average number of shares outstanding used in the computation of diluted earnings per share, as the effect is dilutive. Such dilutive effect of the potential shares is included in the computation of diluted earnings per share until the number of shares to be distributed to employees is resolved in the following year.

27. GOVERNMENT GRANTS

The Company applied for the subsidy program “Large-to-Small Low Carbon and Intelligent Manufacturing Upgrade and Transformation”, proposed by the Ministry of Economic Affairs. The subsidies approved amounted to NT\$18,000 thousand. As of March 31, 2025, a total of NT\$2,935 thousand has been recognized as subsidy income, which was recorded in other income. The Company provided a performance letter of guarantee as collateral, which amounted to NT\$18,000 thousand.

28. CASH FLOW INFORMATION

a. Non-cash transactions

The Group entered into the following non-cash investing and financing activities which were not reflected in the consolidated statements of cash flows for the three months ended March 31, 2025 and 2024:

	For the Three Months Ended March 31	
	2025	2024
Additions of property, plant and equipment	\$ (80,420)	\$ (116,837)
Changes in prepayments for purchases	4,998	(21,591)
Changes in payables for purchase of equipment	<u>(15,415)</u>	<u>(8,186)</u>
Payments for acquisition of property, plant and equipment	<u>\$ (90,837)</u>	<u>\$ (146,614)</u>

b. Changes in liabilities arising from financing activities

For the three months ended March 31, 2025

	January 1, 2025	Cash Flows	Non-cash Changes			March 31, 2025
			Lease Change	Finance Costs	Exchange Rate Impact	
Guarantee deposits received	\$ 10,381	\$ 1,707	\$ -	\$ -	\$ 44	\$ 12,132
Lease liabilities	<u>160,911</u>	<u>(15,654)</u>	<u>98,458</u>	<u>1,075</u>	<u>38</u>	<u>244,828</u>
	<u>\$ 171,292</u>	<u>\$ (13,947)</u>	<u>\$ 98,458</u>	<u>\$ 1,075</u>	<u>\$ 82</u>	<u>\$ 256,960</u>

For the three months ended March 31, 2024

	January 1, 2024	Cash Flows	Non-cash Changes			March 31, 2024
			Lease Change	Finance Costs	Exchange Rate Impact	
Guarantee deposits received	\$ 11,709	\$ 1,842	\$ -	\$ -	\$ 20	\$ 13,571
Lease liabilities	<u>192,920</u>	<u>(13,563)</u>	<u>5,686</u>	<u>710</u>	<u>46</u>	<u>185,799</u>
	<u>\$ 204,629</u>	<u>\$ (11,721)</u>	<u>\$ 5,686</u>	<u>\$ 710</u>	<u>\$ 66</u>	<u>\$ 199,370</u>

29. CAPITAL MANAGEMENT

The objective of the Group's capital management is maintaining a good capital structure and to ensure the ability to operate continuously, in order to provide returns to shareholders. The Group's capital structure management strategies were based on the industry size of the Company and its subsidiaries, industry's future growth, product roadmaps, and changes in the external environment and other factors. The Group plans the required capacity and the necessary plant and equipment to achieve this capacity and the corresponding capital expenditure according to those strategies. The Group then calculates the required working capital and cash based on industry characteristics, and estimates the possible product margins, operating margin and cash flow. In order to determine the most appropriate capital structure, the Group takes into consideration cyclical fluctuations in industrial, product life cycle and other risk factors.

30. FINANCIAL INSTRUMENTS

a. Fair value of financial instruments not measured at fair value

The Group's management considers that the book value of financial instruments that are not measured at fair value in the consolidated financial statements approximate the fair values.

b. Fair value of financial instruments measured at fair value on a recurring basis

1) Fair value hierarchy

March 31, 2025

	Level 1	Level 2	Level 3	Total
<u>Financial assets at FVTPL</u>				
Mutual funds	\$ 40,749	\$ -	\$ -	\$ 40,749

December 31, 2024

	Level 1	Level 2	Level 3	Total
<u>Financial assets at FVTPL</u>				
Mutual funds	\$ 40,595	\$ -	\$ -	\$ 40,595

March 31, 2024

	Level 1	Level 2	Level 3	Total
<u>Financial assets at FVTPL</u>				
Mutual funds	\$ 50,199	\$ -	\$ -	\$ 50,199

Financial assets at FVTOCI

Investments in equity instruments				
- unlisted shares	\$ -	\$ -	\$ 130	\$ 130

There were no transfers between Levels 1 and 2 in the current and prior periods.

2) Reconciliation of Level 3 fair value measurements of financial instruments

For the three months ended March 31, 2024

Financial Assets	Financial Assets at FVTOCI Equity Instruments
Balance at beginning of period	\$ 128
Recognized in other comprehensive loss (included in unrealized gain (loss) on financial assets at FVTOCI)	<u>2</u>
Balance at end of period	<u>\$ 130</u>

3) Valuation techniques and inputs applied for Level 3 fair value measurement

The fair values of unlisted equity securities were determined using the market approach. The market approach is used to arrive at their fair values, for which the recent financing activities of investees, the market transaction prices of the similar companies and market conditions are considered. The significant unobservable inputs are as follows. The lower the discount for lack of marketability, the higher the fair value of the shares.

	March 31, 2025	December 31, 2024	March 31, 2024
Discount for lack of marketability	-	-	30%

If the inputs to the valuation model were changed to reflect reasonably possible alternative assumptions while all the other variables were held constant, the fair value of the shares would increase (decrease) as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Discount for lack of marketability			
1% increase	\$ -	\$ -	\$ (2)
1% decrease	\$ -	\$ -	\$ 2

c. Categories of financial instruments

	March 31, 2025	December 31, 2024	March 31, 2024
<u>Financial assets</u>			
Financial assets at FVTPL			
Mandatorily classified as at FVTPL	\$ 40,749	\$ 40,595	\$ 50,199
Financial assets at amortized cost			
Cash and cash equivalents	3,861,462	4,342,605	4,841,260
Financial assets at amortized cost	153,601	154,906	76,478
Notes and accounts receivable, net	235,172	216,698	234,289
Accounts receivable from related parties	89,607	88,123	102,139
Other receivables	25,440	30,260	17,430
Other receivables from related parties	459	449	12
Financial assets at FVTOCI			
Equity instruments	-	-	130
	<u>\$ 4,406,490</u>	<u>\$ 4,873,636</u>	<u>\$ 5,321,937</u>
<u>Financial liabilities</u>			
Financial liabilities at amortized cost			
Notes and accounts payable	\$ 313,975	\$ 306,317	\$ 301,003
Accounts payable to related parties	7,165	3,127	4,087
Other payables	2,173,658	2,403,427	1,564,952
Other payables to related parties	41,425	34,393	92,563
	<u>\$ 2,536,223</u>	<u>\$ 2,747,264</u>	<u>\$ 1,962,605</u>

d. Financial risk management objectives and policies

The Group's principal financial risk management objective is to manage the market risk, credit risk and liquidity risk related to its operating activities. The Group identifies, measures and manages the aforementioned risks based on the Group's policies and risk appetite.

The Group has established appropriate policies, procedures and internal controls for financial risk management. Before entering into significant transactions, approval process by the Board of Directors must be carried out based on related protocols and internal control procedures. The Group complies with its financial risk management policies.

1) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprise currency risk (see (a) below) and interest rate risk (see (b) below).

In practice, it is rarely the case that a single risk variable will change independently from other risk variables. There are usually interdependencies between risk variables. However, the sensitivity analysis disclosed below does not take into account the interdependencies between risk variables.

There has been no change to the Group's exposure to market risks or the manner in which these risks are managed and measured.

a) Foreign currency risk

The Group's exposure to the risk of changes in foreign exchange rates relates primarily to the Group's operating activities (when revenue or expense is denominated in a different currency from the Group's functional currency) and the Group's net investments in foreign subsidiaries. The purpose of the Group's management of the exchange rate risk is for the purpose of hedging and not for profit.

The Group has certain foreign currency receivables to be denominated in the same foreign currency with certain foreign currency payables, therefore natural hedge is applied. Furthermore, as net investments in foreign subsidiaries are for strategic purposes, they are not hedged by the Group.

The carrying amounts of the Group's foreign currency denominated monetary assets and monetary liabilities (including those eliminated on consolidation) are set out in Note 34.

Sensitivity analysis

The Group is mainly exposed to the USD.

The following table details the Group's sensitivity to a 10% change in the functional currency against the relevant foreign currencies. The sensitivity analysis included only outstanding foreign currency denominated monetary items, and adjusts their translation at the end of the reporting period for a 10% change in foreign currency rates. A positive number below indicates a change in pre-tax profit associated with the functional currency strengthening 10% against the relevant currency.

	Currency USD Impact	
	For the Three Months Ended	
	March 31	
	2025	2024
Profit or loss	\$ 12,301	\$ 14,250

b) Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group is exposed to interest rate risk because entities in the Group borrow funds at both fixed and floating interest rates. The Group is also exposed to interest rate risk related to its investments in floating rate debt instruments. The risk is managed by the Group by maintaining an appropriate mix of fixed and floating rate borrowings.

The carrying amounts of the Group's financial assets and financial liabilities with exposure to interest rates at the end of the reporting period were as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Fair value interest rate risk			
Financial assets	\$ 676,845	\$ 174,577	\$ 78,878
Financial liabilities	244,828	160,911	185,799
Cash flow interest rate risk			
Financial assets	3,330,680	4,316,326	4,831,408

Sensitivity analysis

The sensitivity analysis below was determined based on the Group's exposure to interest rates for non-derivative instruments at the end of the reporting period. For floating rate liabilities, the analysis was prepared assuming the amount of each liability outstanding at the end of the reporting period was outstanding for the whole year.

If interest rates had been changed by 10 basis points and all other variables were held constant, the Group's pre-tax profit for the three months ended March 31, 2025 and 2024 would change by NT\$833 thousand and NT\$1,208 thousand, respectively, which was mainly due to fluctuations in net asset's variable interest rate.

2) Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the Group. As at the end of the reporting period, the Group's maximum exposure to credit risk, which would cause a financial loss to the Group due to the failure of the counterparty to discharge its obligation, could be equal to the total of the carrying amount of the respective recognized financial assets as stated in the consolidated balance sheets.

Customer credit risk is managed by each business unit subject to the Group's established policy, procedures and control relating to customer credit risk management. Credit limits are established for all customers based on their financial position, rating from credit rating agencies, historical experience, prevailing economic condition and the Group's internal rating criteria etc. Credit risk of certain customers is also managed by carrying out credit enhancement procedures such as requesting for prepayment.

The Group transacts with a large number of unrelated customers and thus, credit risk is not highly concentrated.

Credit risk from balances with banks, fixed income securities and other financial instruments is managed by the Group's treasury in accordance with the Group's policy. The Group only transacts with counterparties approved by the internal control procedures, which are banks and financial

institutions, companies and government entities with good credit rating and with no significant default risk. Consequently, there is no significant credit risk for these counterparties.

3) Liquidity risk

The Group's objective is to finance its operations and mitigate the effects of fluctuations in cash flows through the use of cash and cash equivalents, equity investments and bank loans. In addition, management monitors the utilization of bank borrowings and ensures compliance with loan covenants.

The Group relies on bank borrowings as a significant source of liquidity. As of March 31, 2025, December 31, 2024 and March 31, 2024, the Group had available unutilized short-term bank loan facilities set out in (b) below.

a) Liquidity and interest rate risk tables for non-derivative financial liabilities

The following table details the Group's remaining contractual maturities for its non-derivative financial liabilities with agreed upon repayment periods. The table has been drawn up based on the undiscounted cash flows of financial liabilities from the earliest date on which the Group can be required to pay. The table includes both interest and principal cash flows. Specifically, bank loans with a repayment on demand clause were included in the earliest time band regardless of the probability of the banks choosing to exercise their rights. The maturity dates for other non-derivative financial liabilities were based on the agreed upon repayment dates.

March 31, 2025

	On Demand or Less than 6 Months	6-12 Months	1-2 Years	2-5 Years	5+ Years	Total
Notes and accounts payable (related parties included)	\$ 321,140	\$ -	\$ -	\$ -	\$ -	\$ 321,140
Other payables (related parties included)	2,077,062	76,557	61,464	-	-	2,215,083
Lease liabilities	<u>40,539</u>	<u>33,223</u>	<u>58,511</u>	<u>83,772</u>	<u>47,521</u>	<u>263,566</u>
	<u>\$ 2,438,741</u>	<u>\$ 109,780</u>	<u>\$ 119,975</u>	<u>\$ 83,772</u>	<u>\$ 47,521</u>	<u>\$ 2,799,789</u>

Additional information about the maturity analysis for lease liabilities:

	Less than 1 Year	1-5 Years	5-10 Years	10-15 Years	15-20 Years	20+ Years
Lease liabilities	<u>\$ 73,762</u>	<u>\$ 142,283</u>	<u>\$ 11,270</u>	<u>\$ 11,270</u>	<u>\$ 11,270</u>	<u>\$ 13,711</u>

December 31, 2024

	On Demand or Less than 6 Months	6-12 Months	1-2 Years	2-5 Years	5+ Years	Total
Notes and accounts payable (related parties included)	\$ 309,444	\$ -	\$ -	\$ -	\$ -	\$ 309,444
Other payables (related parties included)	2,210,403	227,417	-	-	-	2,437,820
Lease liabilities	<u>30,966</u>	<u>22,454</u>	<u>38,935</u>	<u>35,352</u>	<u>48,084</u>	<u>175,791</u>
	<u>\$ 2,550,813</u>	<u>\$ 249,871</u>	<u>\$ 38,935</u>	<u>\$ 35,352</u>	<u>\$ 48,084</u>	<u>\$ 2,923,055</u>

Additional information about the maturity analysis for lease liabilities:

	Less than 1 Year	1-5 Years	5-10 Years	10-15 Years	15-20 Years	20+ Years
Lease liabilities	<u>\$ 53,420</u>	<u>\$ 74,287</u>	<u>\$ 11,270</u>	<u>\$ 11,270</u>	<u>\$ 11,270</u>	<u>\$ 14,274</u>

March 31, 2024

	On Demand or Less than 6 Months	6-12 Months	1-2 Years	2-5 Years	5+ Years	Total
Notes and accounts payable (related parties included)	\$ 305,090	\$ -	\$ -	\$ -	\$ -	\$ 305,090
Other payables (related parties included)	1,520,492	81,419	55,604	-	-	1,657,515
Lease liabilities	<u>32,461</u>	<u>24,205</u>	<u>39,098</u>	<u>56,952</u>	<u>49,775</u>	<u>202,491</u>
	<u>\$ 1,858,043</u>	<u>\$ 105,624</u>	<u>\$ 94,702</u>	<u>\$ 56,952</u>	<u>\$ 49,775</u>	<u>\$ 2,165,096</u>

Additional information about the maturity analysis for lease liabilities:

	Less than 1 Year	1-5 Years	5-10 Years	10-15 Years	15-20 Years	20+ Years
Lease liabilities	<u>\$ 56,666</u>	<u>\$ 96,050</u>	<u>\$ 11,270</u>	<u>\$ 11,270</u>	<u>\$ 11,270</u>	<u>\$ 15,965</u>

b) Financing facilities

	March 31, 2025	December 31, 2024	March 31, 2024
Short-term borrowings amount			
Amount unused	<u>\$ 1,538,000</u>	<u>\$ 1,738,000</u>	<u>\$ 1,738,000</u>

31. TRANSACTIONS WITH RELATED PARTIES

Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. Besides information disclosed elsewhere in the other notes, details of transactions between the Group and other related parties are disclosed as follows:

a. Related party name and category

Related Party Name	Related Party Category	Relationship with the Group
Sheng-Lin Tseng	Substantive related party	Chairman of the Company
Lifeshine Co., Ltd. (Lifeshine)	Substantive related party	Substantive related party
BIBAU (CHINA) CO., LIMITED (BIBAU)	Other related party	Director of PUBAI
Pu Hsing Enterprise Co., Ltd. (Pu Hsing)	Other related party	Director of Pro-partner
Taipei City Pro-partner Technology and Human Development Foundation (Pro-partner Foundation)	Other related party	Pro-partner is its sole founder
Laser Solution Technology Co., Ltd. (Laser Solution)	Other related party	Supervisor of Pro-partner (from June 3, 2021 to June 2, 2024)
Pu-Lin Ltd. (Pu-Lin)	Other related party	Related party in substance of Pro-partner

(Continued)

Related Party Name	Related Party Category	Relationship with the Group
Xinlin Enterprise Co., Ltd. (Xinlin)	Other related party	Related party in substance of Pro-partner
Xinlin Investment Co., Ltd. (Xinlin Investment)	Other related party	Related party in substance of Pro-partner
Uni-President Enterprises Corp. (Uni-President)	Other related party	Director of the Company
Tung-Ju Enterprise Corp. (Tung-Ju)	Other related party	Subsidiary of a director of the Company
Tung Hsyung Co., Ltd. (Tung Hsyung)	Other related party	Subsidiary of a director of the Company
Uni-President Vender Corp. (Uni-President Vender)	Other related party	Subsidiary of a director of the Company
Tong-Yo Co., Ltd. (Tong-Yo)	Other related party	Subsidiary of a director of the Company
RSI, Retail Support International Corp. (Retail Support)	Other related party	Subsidiary of a director of the Company
Sheng-Miao Industrial Corp. (Sheng-Miao)	Other related party	Subsidiary of a director of the Company
Tung-Bo Enterprise Corp. (Tung-Bo)	Other related party	Subsidiary of a director of the Company
Xin-Tung Enterprises Corp. (Xin-Tung)	Other related party	Subsidiary of a director of the Company
Tong-Yeen Enterprise Corp. (Tong-Yeen)	Other related party	Subsidiary of a director of the Company
Wei-Tong Enterprise Corp. (Wei-Tong)	Other related party	Subsidiary of a director of the Company
President Pharmaceutical Corp. (President Pharmaceutical)	Other related party	Subsidiary of a director of the Company
President Transnet Corp. (President Transnet)	Other related party	Subsidiary of a director of the Company
President Collect Services Corp. (President Collect Services)	Other related party	Subsidiary of a director of the Company
Presco Netmarketing, Inc. (Presco Netmarketing)	Other related party	Subsidiary of a director of the Company
Yahoo! Taiwan Holdings Ltd. (Yahoo)	Other related party	Subsidiary of a director of the Company
President (Shanghai) Health Product Trading Company Ltd. (President (Shanghai) Health Product Trading)	Other related party	Subsidiary of a director of the Company
Uni-President Shanghai Management Consulting Co., Ltd. (Uni-President Shanghai Management Consulting)	Other related party	Subsidiary of a director of the Company
Kunshan President Enterprises Food Co., Ltd. (Kunshan President)	Other related party	Subsidiary of a director of the Company
President Enterprises (Inner Mongolia) Co., Ltd. (Inner Mongolia President)	Other related party	Subsidiary of a director of the Company
President (Shanghai) Trading Co., Ltd. (President (Shanghai) Trading)	Other related party	Subsidiary of a director of the Company

(Continued)

Related Party Name	Related Party Category	Relationship with the Group
Uni-President Trading (Kunshan) Co., Ltd. (Uni-President Trading (Kunshan))	Other related party	Subsidiary of a director of the Company
Henan President Enterprises Co., Ltd. (Henan President)	Other related party	Subsidiary of a director of the Company
Zhengzhou President Enterprises Co., Ltd. (Zhengzhou President)	Other related party	Subsidiary of a director of the Company
Jinan President Enterprises Co., Ltd. (Jinan President)	Other related party	Subsidiary of a director of the Company
Xinjiang President Enterprises Food Co., Ltd. (Xinjiang President)	Other related party	Subsidiary of a director of the Company
Hefei President Enterprises Co., Ltd. (Hefei President)	Other related party	Subsidiary of a director of the Company
Nanchang President Enterprises Co., Ltd. (Nanchang President)	Other related party	Subsidiary of a director of the Company
Shaanxi President Enterprises Co., Ltd. (Shaanxi President)	Other related party	Subsidiary of a director of the Company
Changsha President Enterprises Co., Ltd. (Changsha President)	Other related party	Subsidiary of a director of the Company
Uni-President Enterprises (China) Investment Corp. (Uni-President Enterprises (China) Investment)	Other related party	Subsidiary of a director of the Company
Ton Yi (China) Investment Co., Ltd. (Ton Yi (China) Investment)	Other related party	Subsidiary of a director of the Company
Harbin Uni-President Food Co., Ltd. (Harbin Uni-President)	Other related party	Subsidiary of a director of the Company
Shenyang Uni-President Food Co., Ltd. (Shenyang Uni-President)	Other related party	Subsidiary of a director of the Company
GK BIO INTERNATIONAL SDN. BHD.	Associate	Investee of the Company accounted for using the equity method (Concluded)

b. Sales of goods

Line Item	Related Party Category/Name	For the Three Months Ended March 31	
		2025	2024
Sales	Associate	\$ 15,148	\$ 7,395
	Substantive related party	132	-
	Other related party	<u>54,521</u>	<u>75,825</u>
		<u>\$ 69,801</u>	<u>\$ 83,220</u>

The sales price for the related parties and the price for the third-party MLM member customers were determined based on mutual consent. There is no significant difference regarding the terms and conditions for the related parties and for the third parties.

c. Purchases of goods

Line Item	Related Party Category/Name	For the Three Months Ended March 31	
		2025	2024
Purchases of goods	Changsha President	\$ 59,114	\$ 93,590
	Nanchang President	41,830	45,287
	Other related party	<u>45,699</u>	<u>21,512</u>
		<u>\$ 146,643</u>	<u>\$ 160,389</u>

Purchases for the related parties were determined based on mutual consent. There is no significant difference regarding the terms and conditions for the related parties and for the third parties.

d. Contract liabilities

Line Item	Related Party Category/Name	March 31, 2025	December 31, 2024	March 31, 2024
Contract liabilities	Other related party	<u>\$ -</u>	<u>\$ 155</u>	<u>\$ 426</u>

e. Receivables from related parties

Line Item	Related Party Category/Name	March 31, 2025	December 31, 2024	March 31, 2024
Accounts receivable from related parties	Tung Hsyng	\$ 40,172	\$ 43,845	\$ 36,344
	Tung-Ju	17,254	15,510	15,198
	GK BIO INTER- NATIONAL SDN. BHD.	15,360	8,485	14,264
	Retail Support	7,666	-	11,979
	Kunshan President	-	-	18,677
	Other related party	<u>9,155</u>	<u>20,283</u>	<u>5,677</u>
		<u>\$ 89,607</u>	<u>\$ 88,123</u>	<u>\$ 102,139</u>
Other receivables from related parties	BIBAU	\$ 459	\$ 449	\$ -
	Pu Hsing	<u>-</u>	<u>-</u>	<u>12</u>
		<u>\$ 459</u>	<u>\$ 449</u>	<u>\$ 12</u>

f. Payables to related parties

Line Item	Related Party Category/Name	March 31, 2025	December 31, 2024	March 31, 2024
Accounts payable to related parties	Changsha President	\$ 2,337	\$ 921	\$ 1,446
	Nanchang President	1,833	704	959
	Hefei President	1,201	525	310

(Continued)

Line Item	Related Party Category/Name	March 31, 2025	December 31, 2024	March 31, 2024
Accounts payable to related parties	Uni-President Trading (Kunshan)	\$ 1,103	\$ 476	\$ -
	Shaanxi President	-	501	-
	Xinjiang President	-	-	1,024
	Other related party	<u>691</u>	<u>-</u>	<u>348</u>
		<u>\$ 7,165</u>	<u>\$ 3,127</u>	<u>\$ 4,087</u>
Other payables to related parties	Tung Hsyung	\$ 26,274	\$ 17,137	\$ 24,954
	Tung-Ju	5,717	7,398	10,155
	Other related party	<u>9,434</u>	<u>9,858</u>	<u>10,516</u>
		<u>\$ 41,425</u>	<u>\$ 34,393</u>	<u>\$ 45,625</u>

(Concluded)

g. Prepayments

Line Item	Related Party Category/Name	March 31, 2025	December 31, 2024	March 31, 2024
Prepayments	Uni-President Shanghai Management Consulting	\$ 13,395	\$ -	\$ -
	Changsha President	-	10,050	6,811
	Nanchang President	-	-	4,734
	Associate	203	203	450
	Other related party	<u>20,621</u>	<u>21,847</u>	<u>6,924</u>
		<u>\$ 34,219</u>	<u>\$ 32,100</u>	<u>\$ 18,919</u>

h. Lease arrangements

Line Item	Related Party Category/Name	March 31, 2025	December 31, 2024	March 31, 2024
Lease liabilities	Pu-Lin	\$ 6,419	\$ 6,419	\$ 6,419
	Substantive related party	<u>3,061</u>	<u>3,353</u>	<u>4,224</u>
		<u>\$ 9,480</u>	<u>\$ 9,772</u>	<u>\$ 10,643</u>

For the Three Months Ended
March 31

Related Party Category	2025	2024
<u>Interest expense</u>		
Substantive related party	<u>\$ 8</u>	<u>\$ 11</u>

The rental paid to the above related party is similar to general market rental prices, and rental is paid each remittance one month and once every six months, respectively.

i. Other transactions with related parties

Line Item	Related Party Category/Name	March 31, 2025	December 31, 2024	March 31, 2024
Refundable deposits	Other related party	<u>\$ 2,122</u>	<u>\$ 2,112</u>	<u>\$ 2,104</u>
Guarantee deposits received	Other related party	<u>\$ 366</u>	<u>\$ 358</u>	<u>\$ 353</u>
Advance receipts (classified as other current liabilities)	Other related party	<u>\$ 25</u>	<u>\$ -</u>	<u>\$ 25</u>

Line Item	Related Party Category/Name	For the Three Months Ended March 31	
		2025	2024
Operating costs - freight expense	Other related party	<u>\$ 5</u>	<u>\$ 3</u>
Operating costs - inspection expense	Other related party	<u>\$ -</u>	<u>\$ 6</u>
Selling and marketing expenses - advertisement expense	Other related party	<u>\$ 5,698</u>	<u>\$ 4,000</u>
Selling and marketing expenses - commissions expense	Other related party	<u>\$ 4,085</u>	<u>\$ 4,333</u>
Selling and marketing expenses - freight expense	Other related party	<u>\$ 4,084</u>	<u>\$ 4,398</u>
Selling and marketing expenses - other expense	Other related party	<u>\$ 105</u>	<u>\$ 3</u>
General and administrative expenses - freight expense	Other related party	<u>\$ 3</u>	<u>\$ 4</u>
Research and development expenses - inspection expense	Other related party	<u>\$ 87</u>	<u>\$ 79</u>
Research and development expenses - freight expense	Other related party	<u>\$ 21</u>	<u>\$ 27</u>
Rental income	Other related party	<u>\$ 3</u>	<u>\$ 3</u>
Other income	Other related party	<u>\$ 9</u>	<u>\$ 9</u>

The terms and conditions of the above-mentioned related party transactions are similar to those of general non-related parties. The calculation method and payment terms are the same as the general membership in accordance with the regulations of the Business Manual, and rental prices were similar to those of general transactions. The term of collection was either in monthly installments or in full at the beginning of each year.

j. Compensation of key management personnel

	For the Three Months Ended March 31	
	2025	2024
Short-term employee benefits	\$ 47,294	\$ 45,826
Post-employment benefits	<u>98</u>	<u>98</u>
	<u>\$ 47,392</u>	<u>\$ 45,924</u>

The remuneration of directors and key executives, as determined by the remuneration committee, was based on the performance of individuals and market trends.

32. ASSETS PLEDGED AS COLLATERAL OR FOR SECURITY

The following assets were provided as collateral for long-term and short-term secured loans, Chinese Petroleum Corporation natural gas, leasing land and operating center from science-based parks:

	March 31, 2025	December 31, 2024	March 31, 2024
Property, plant and equipment - land	\$ 3,004,762	\$ 3,004,762	\$ 3,004,762
Property, plant and equipment - building	918,066	913,213	932,757
Pledged time deposits (classified as financial assets at amortized cost - non-current)	<u>12,813</u>	<u>16,533</u>	<u>28,520</u>
	<u>\$ 3,935,641</u>	<u>\$ 3,934,508</u>	<u>\$ 3,966,039</u>

Secured bank facilities used in response to operating funds by the Group's property, plant and equipment - land/building as of March 31, 2025 and December 31, 2024 and March 31, 2024 are as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Short-term financing facilities	\$ 1,238,000	\$ 1,238,000	\$ 1,238,000
Medium and long-term financing facilities	<u>450,000</u>	<u>450,000</u>	<u>1,000,000</u>
	<u>\$ 1,688,000</u>	<u>\$ 1,688,000</u>	<u>\$ 2,238,000</u>

33. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNIZED COMMITMENTS

Significant contingencies and unrecognized commitments of the Group are as follows:

- The Company's guarantee notes issued to banks for credit lines amounted to NT\$300,000 thousand as of March 31, 2025.
- Details of significant constructions in progress and outstanding contracts of property, plant and equipment as of March 31, 2025 were as follows:

Nature of Contract	Contract Amount	Amount Paid	Outstanding Balance
Plant and machinery	<u>\$ 458,932</u>	<u>\$ 132,677</u>	<u>\$ 326,255</u>

- c. For operational needs, Pro-partner established operational bases in Taoyuan, Hsinchu, Taichung, Hualien, Tainan and Kaohsiung. The information concerning the operating leases as of March 31, 2025 is listed below:

Operating Location	Lessor	Lease Period	Monthly Rental
Taoyuan City	Passion Technology Co., Ltd.	2020.05.01-2025.04.30	\$280-300
Hsinchu City	Lin, Zhuang-Long, Wu, Yi-Wan	2021.11.01-2026.10.31	350-368
Taichung City	Nan shan life insurance co. ltd	2022.05.01-2027.04.30	555-572
Taichung City	Pu-Lin Ltd.	2007.11.01-2027.11.01 (Note)	220
Taichung City	Pu-Lin Ltd.	2010.04.01-2030.03.31 (Note)	129
Tainan City	Cathay Life Insurance Co., Ltd.	2021.08.01-2026.07.31	418-444
Kaohsiung City	Kazu Kuwae Trading Co., Ltd.	2021.12.01-2025.03.31	71
Hualien City	Liou, Chuen-Hou, Liou, Chuen-Lung	2024.09.01-2026.08.31	130
Taoyuan City	Taoyuan Irrigation Association	2025.02.01-2030.01.31	402
Taoyuan City	Lilong Fiber Industrial Co., Ltd.	2025.01.01-2029.12.31	829

Note: In order to improve Pro-partner's operational efficiency, the quality of member's services and the operational needs, and leasing of new base for relocation in response to the cross-border merger and the expansion of business, the board of directors resolved on September 22, 2022 to end the lease early, and the relevant termination conditions will be handled in accordance with the contract specifications or subsequent agreements.

34. SIGNIFICANT FINANCIAL ASSETS AND LIABILITIES DENOMINATED IN FOREIGN CURRENCIES

The Group's significant financial assets and liabilities denominated in foreign currencies aggregated by the foreign currencies other than functional currencies of the entities in the Group and the related exchange rates between the foreign currencies and the respective functional currencies were as follows:

March 31, 2025

	Foreign Currency	Exchange Rate	Carrying Amount
<u>Financial assets</u>			
Monetary items			
USD	\$ 3,570	33.205 (USD:NTD)	\$ <u>118,520</u>
USD	274	7.175 (USD:CNY)	\$ <u>9,006</u>
<u>Financial liabilities</u>			
Monetary items			
USD	86	33.205 (USD:NTD)	\$ <u>2,865</u>
USD	50	7.175 (USD:CNY)	\$ <u>1,649</u>

December 31, 2024

	Foreign Currency	Exchange Rate	Carrying Amount
<u>Financial assets</u>			
Monetary items			
USD	\$ 2,759	32.785 (USD:NTD)	\$ <u>90,467</u>
USD	274	7.189 (USD:CNY)	\$ <u>8,835</u>

Financial liabilities

Monetary items			
USD	538	32.785 (USD:NTD)	\$ <u>17,626</u>
USD	60	7.189 (USD:CNY)	\$ <u>1,554</u>

March 31, 2024

	Foreign Currency	Exchange Rate	Carrying Amount
<u>Financial assets</u>			
Monetary items			
USD	\$ 4,416	32.000 (USD:NTD)	\$ <u>141,312</u>
USD	32	7.095 (USD:CNY)	\$ <u>10,240</u>

Financial liabilities

Monetary items			
USD	101	32.000 (USD:NTD)	\$ <u>3,232</u>
USD	182	7.095 (USD:CNY)	\$ <u>5,824</u>

For the three months ended March 31, 2025 and 2024, realized and unrealized net foreign exchange gains were NT\$1,045 thousand and NT\$5,717 thousand, respectively. It is impractical to disclose net foreign exchange gains by each significant foreign currency due to the variety of the foreign currency transactions and functional currencies of the entities in the Group.

35. SEPARATELY DISCLOSED ITEMS

a. Information about significant transactions:

- 1) Financing provided to others: None;
- 2) Endorsements/guarantees provided: None;
- 3) Significant marketable securities held (excluding investments in subsidiaries, associates and jointly controlled entities): None;
- 4) Total purchases from or sales to related parties of at least NT\$100 million or 20% of the paid-in capital: Table 1;
- 5) Receivables from related parties amounting to at least NT\$100 million or 20% of the paid-in capital: Table 2;

- 6) Others: Intercompany relationships and significant intercompany transactions: Table 3;
- b. Information on investees: Table 4;
- c. Information on investments in mainland China
 - 1) The name of the investee in mainland China, the main businesses and products, its issued capital, method of investment, information on inflow or outflow of capital, percentage of ownership, net income (losses) of the investee, investment income (losses), ending balance, amount received as dividends from the investee, and the limitation on investee: Table 5.
 - 2) Significant direct or indirect transactions with the investee, its prices and terms of payment and unrealized gain or loss: None;

36. SEGMENTS INFORMATION

The Group determined its operating segments based on business activities, with discrete financial information regularly reported through the Group's internal reporting protocols to the Group's chief operating decision-maker. The Group is organized into several business units based on its marketing channels and services. As of March 31, 2025 and 2024, the Group had the following segments: MLM (Multi-level marketing), Distributors, ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) and Sales channel.

Management monitors the operating results of its business units separately for making decisions about resource allocation and performance assessment. Segment performance is evaluated based on operating profit or loss and is measured based on accounting policies consistent with those in the consolidated financial statements. However, non-operating income and expenses and income taxes are managed on a company basis and are not allocated to operating segments.

Transfer prices between operating segments are determined on an arm's length basis in a manner similar to transactions with third parties.

Segment's description: MLM is a direct seller of Pro-partner Ltd., including the Company's development and manufacturing products for Pro-partner Ltd., Distributors includes GRAPE KING BIO's self-owned brand products, ODM/OEM includes ODM/OEM in Taiwan and Shanghai, and Sales channel is the Group's business of selling products from other companies for the purpose of building its own brand channels.

Inter-segment revenues refer to transactions between segments that have been eliminated in the consolidated financial statements.

Segment profit (loss) is profit from operation, segment gross margin, segment operating revenue minus segment operating costs, minus directly attributable segment operating expense and distributable common expenses of the Group.

Adjustment/elimination: Inter-segment revenues are eliminated on consolidation and recorded under the "adjustment and elimination" column. Other adjustments and eliminations which have no significant influence, are not disclosed.

Segment revenue and results

The following was an analysis of the Group's revenue and results from continuing operations by reportable segments:

For the three months ended March 31, 2025

	MLM	Distribution	ODM/OEM	Sales Channel	Adjustment/ Elimination	Total
Revenue from external customers	\$ 1,678,068	\$ 160,031	\$ 249,971 (Note)	\$ 164,225	\$ -	\$ 2,252,295
Inter-segment revenue	<u>306,250</u>	<u>54,902</u>	<u>2,220</u>	<u>347</u>	<u>(363,719)</u>	<u>-</u>
Segment revenue	<u>\$ 1,984,318</u>	<u>\$ 214,933</u>	<u>\$ 252,191</u>	<u>\$ 164,572</u>	<u>\$ (363,719)</u>	<u>\$ 2,252,295</u>
Segment income	<u>\$ 335,983</u>	<u>\$ 3,789</u>	<u>\$ 22,819</u>	<u>\$ 1,496</u>	<u>\$ 12,019</u>	<u>\$ 376,106</u>

Note: ODM/OEM revenues come from external customers in Taiwan and Shanghai amounted to NT\$157,546 thousand and NT\$92,425 thousand, respectively.

For the three months ended March 31, 2024

	MLM	Distribution	ODM/OEM	Sales Channel	Adjustment/ Elimination	Total
Revenue from external customers	\$ 1,782,162	\$ 187,661	\$ 206,601 (Note)	\$ 171,095	\$ -	\$ 2,347,519
Inter-segment revenue	<u>335,018</u>	<u>64,637</u>	<u>7,861</u>	<u>-</u>	<u>(407,516)</u>	<u>-</u>
Segment revenue	<u>\$ 2,117,180</u>	<u>\$ 252,298</u>	<u>\$ 214,462</u>	<u>\$ 171,095</u>	<u>\$ (407,516)</u>	<u>\$ 2,347,519</u>
Segment income	<u>\$ 383,150</u>	<u>\$ 7,410</u>	<u>\$ 31,848</u>	<u>\$ 2,932</u>	<u>\$ 10,991</u>	<u>\$ 436,331</u>

Note: ODM/OEM revenues come from external customers in Taiwan and Shanghai amounted to NT\$93,409 thousand and NT\$113,192 thousand, respectively.

TABLE 1**GRAPE KING BIO LTD. AND SUBSIDIARIES****TOTAL PURCHASES FROM OR SALES TO RELATED PARTIES OF AT LEAST NT\$100 MILLION OR 20% OF THE PAID-IN CAPITAL****FOR THE THREE MONTHS ENDED MARCH 31, 2025****(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)**

Company Name	Related Party	Nature of Relationship	Transaction Details				Abnormal Transaction (Note 1)		Notes/Accounts Payable or Receivable		Note
			Purchases/Sales	Amount	% to Total	Payment Terms	Unit Price	Payment Terms	Ending Balance	% to Total	
Grape King Bio Ltd.	Pro-partner Ltd.	Subsidiary	Sales	\$ 306,250	50.80	30 days after monthly closing	By contract	-	\$ 149,229	38.56	Note 2
Grape King Bio Ltd.	Rivershine Ltd.	Subsidiary	Sales	54,900	9.11	120 days after monthly closing	By contract	-	103,855	26.84	Note 2
Pro-partner Ltd.	Grape King Bio Ltd.	Parent company	Purchases	306,250	90.81	30 days after monthly closing	By contract	-	(149,229)	96.03	Note 2
Rivershine Ltd.	Grape King Bio Ltd.	Parent company	Purchases	54,900	100.00	120 days after monthly closing	By contract	-	(103,855)	100.00	Note 2

Note 1: If the terms of transactions with the related parties are different from normal terms, the difference and the reason for the difference should be declared in the column of unit price or credit period.

Note 2: The transactions have been eliminated in the consolidated financial statements.

GRAPE KING BIO LTD. AND SUBSIDIARIES

RECEIVABLES FROM RELATED PARTIES AMOUNTING TO AT LEAST NT\$100 MILLION OR 20% OF THE PAID-IN CAPITAL

MARCH 31, 2025

(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Company Name	Related Party	Nature of Relationship	Ending Balance	Turnover Days	Overdue		Amount Received in Subsequent Period	Allowance for Bad Debts
					Amount	Action Taken		
Grape King Bio Ltd.	Pro-partner Ltd. Rivershine Ltd.	Subsidiary Subsidiary	\$ 149,229	8.05	\$ -	-	\$ 149,229 21,604	\$ - -
			103,855	1.95	-	-		

Note: The transactions have been eliminated in the consolidated financial statements.

GRAPE KING BIO LTD. AND SUBSIDIARIES

INTERCOMPANY RELATIONSHIPS AND SIGNIFICANT INTERCOMPANY TRANSACTIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2025

(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

No (Note 1)	Company Name	Counterparty	Nature of Relationship (Note 2)	Intercompany Transactions			
				Financial Statement Account	Amount	Terms	Percentage to Consolidated Net Revenue or Total Assets (Note 3)
0	Grape King Bio Ltd.	Pro-partner Ltd.	1	Net revenue from sale of goods	\$ 306,250	By contract	13.60%
			1	Accounts receivable	149,229	By contract	1.00%
		Rivershine Ltd.	1	Accounts receivable	103,855	By contract	0.70%

Note 1: 0 is for the parent company. Subsidiaries are numbered from Arabic numerals 1.

Note 2: There are three types of relations between the parent company and the subsidiaries. Only categories should be identified (There is no need to declare the same interaction between the parent company and the subsidiary, or the same transaction among subsidiaries repeatedly. For example, if the parent company has declared the transaction from parent company to subsidiary, the subsidiary does not need to repeatedly declare the same transaction. If the transaction is between subsidiaries, when one subsidiary has declared the transaction, the other subsidiary does not need to declare the same transaction)

- 1) Represents the transactions from parent company to subsidiary.
- 2) Represents the transactions from subsidiary company to parent.
- 3) Represents the transactions between subsidiaries.

Note 3: When calculating the amount of transaction as a proportion of the consolidated revenue or assets, if it is recognized as items of assets or liabilities, the ending balance should be divided by the consolidated assets; if it is recognized as income or loss, the midterm accumulated amount should be divided by the consolidated assets.

Note 4: The so-called significant transaction refers to materiality of the parent company.

TABLE 4**GRAPE KING BIO LTD. AND SUBSIDIARIES****INFORMATIONS ON INVESTEEES****FOR THE THREE MONTHS ENDED MARCH 31, 2025****(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)**

Investor Company	Investee Company	Location	Main Businesses and Products	Original Investment Amount		Balance as of March 31, 2025			Net Income (Losses) of the Investee	Investment Income (Losses)	Note
				March 31, 2025	December 31, 2024	Shares	Percentage of Ownership (%)	Carrying Amount			
Grape King Bio Ltd.	GRAPE KING INTERNATIONAL INVESTMENT INC. (BVI)	BVI	Investment activities	\$ 1,198,018	\$ 1,198,018	24,890,000	100	\$ 1,202,317	\$ (10,159)	\$ (10,719)	Notes 1, 2 and 3
	Pro-partner Ltd.	Taoyuan, Taiwan	Import and selling of health food, drink, cosmetics, sports apparatus, cleaning products, etc.	15,000	15,000	10,560,000	60	2,699,766	303,860	181,475	Notes 1 and 2
	Rivershine Ltd.	Taoyuan, Taiwan	Import and selling of health food, drinks, daily cosmetics, appliances, etc.	30,000	30,000	3,000,000	100	40,742	2,215	2,215	Note 2
	MYGK BIO SDN.BHD.	Malaysia	Selling of health products	10,982	-	1,500,000	100	10,732	(97)	(97)	Note 2
	GK BIO INTERNATIONAL SDN. BHD.	Malaysia	Import and selling of health products	14,899	14,899	2,100,000	35	87,933	24,908	8,801	Note 1
Pro-partner Ltd.	ELITE PROPARTNER HOLDINGS SDN. BHD.	Malaysia	Selling of health products	7,425	7,425	1,000,000	100	6,172	(75)	Note 4	Note 2
	UVACO MY SDN. BHD.	Malaysia	Selling of health products	37,168	7,348	5,000,000	100	34,912	(381)	Note 4	Note 2
Shanghai Grape King Enterprise Co., Ltd.	PUBAI LIMITED	Hong Kong	Selling of health products	-	-	550,000	55	2,147	(251)	Note 4	Notes 1, 2 and 5

Note 1: The effect from the unrealized profit of the downstream transactions on income tax, which is \$(1,302) thousand has been adjusted.

Note 2: The book value at the end of the period and the current investment gain (loss) recognized have been eliminated in the consolidated financial statements.

Note 3: The current investment gain (loss) recognized by BVI includes the current profit of Shanghai Grape King and Shanghai Rivershine.

Note 4: The share of profits/losses of the investee company is not reflected herein, as such amounts are already included in the share of profits/losses of the investor company.

Note 5: The Company invested in PUBAI LIMITED through its subsidiary Shanghai Grape King Enterprise Co., Ltd. As of March 31, 2025, the capital has not been invested.

TABLE 5

GRAPE KING BIO LTD. AND SUBSIDIARIES

INFORMATION ON INVESTMENTS IN MAINLAND CHINA
FOR THE THREE MONTHS ENDED MARCH 31, 2025

(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Investee Company	Main Businesses and Products	Total Amount of Paid-in Capital	Method of Investment (Note 1)	Accumulated Outflow of Investment from Taiwan as of January 1, 2025	Investment Flows		Accumulated Outflow of Investment from Taiwan as of March 31, 2025	Net Income (Losses) of the Investee Company	Percentage of Ownership	Investment Income (Losses) (Note 2)	Carrying Amount as of March 31, 2025	Accumulated Inward Remittance of Earnings as of March 31, 2025
					Outflow	Inflow						
Shanghai Grape King Enterprise Co., Ltd.	Manufacturing and selling of capsules, tablets, related products and technical services. Warehousing services (excluding dangerous goods), cosmetics wholesale, domestic cargo transportation agency. wholesale of edible agricultural products, domestic cargo transportation agent.	USD 28,900	Note 1(2) Note 3	\$ 847,672 (USD 27,350)	\$ -	\$ -	\$ 847,672 (USD 27,350)	\$ (10,741) Note 2(2)B	100%	\$ (11,226) Note 2(2)B	\$ 1,143,640	\$ -
Shanghai Rivershine Ltd.	Sale of food; transporting road cargo (excluding dangerous goods); wholesale of edible agricultural products; retail of edible agricultural products; sale of agricultural and sideline products; marketing planning; brand management; project planning and public relations services; information consulting services (excluding licensing information consulting services), etc.	USD 650	Note 1(2) Note 4	18,290 (USD 650)	-	-	18,290 (USD 650)	(99) Note 2(3)	100%	(245) Note 2(3)	18,612	-
Shanghai Pujun Trading Co., Ltd.	Manufacturing and selling of capsules, tablets, related products and technical services. Warehousing services (excluding dangerous goods), cosmetics wholesale, domestic cargo transportation agency.	RMB 2,000	Note 1(2) Note 7	-	-	-	-	1,169 Note 2(2)B	51%	596 Note 2(2)B	34,142	-
Shanghai Puxun Supply Chain Management Co., Ltd.	Supply chain management services; network technology services; technical services; technology development; technical consulting, etc.	RMB 2,000	Note 1(2) Note 8	-	-	-	-	(135) Note 2(2)B	67%	(90) Note 2(2)B	2,336	-
Shanghai Puyou Trading Co., Ltd.	Wholesale of edible agricultural products; retail of edible agricultural products; sale of agricultural and sideline products; marketing planning; brand management; vending machine sales, etc.	RMB 2,000	Note 1(2) Note 9	-	-	-	-	909 Note 2(2)B	61%	555 Note 2(2)B	6,610	-
Shanghai Puguang Trading Co., Ltd.	Wholesale of edible agricultural products; retail of edible agricultural products; sale of agricultural and sideline products; marketing planning; brand management; vending machine sales, etc.	RMB 2,000	Note 1(2) Note 10	-	-	-	-	(199) Note 2(2)B	51%	(101) Note 2(2)B	4,562	-
Shanghai Changhong Biotechnology Co., Ltd.	Biotechnology consultation, biotechnology R&D and transfer, import and export of goods or transfers of technology, brand planning, corporate image and marketing planning, conference services, social and economic consulting services, business information consulting, self-owned equipment leasing, domestic cargo transportation agent, sales and online retail of knitted textiles, etc.	USD 700	Note 1(1) Note 5	7,273 (USD 246)	-	-	7,273 (USD 246)	- Note 2(2)B	35.1%	- Note 2(2)B	-	-
Shanghai Xinquan Biotechnology Co., Ltd.	Biotechnology technical technology development, consultation, service and transfer, sales of cosmetic and daily necessities, etc.	RMB 5,000	Note 1(2) Note 6	-	-	-	-	(98) Note 2(2)B	45%	(44) Note 2(2)B	9,234	-

(Continued)

Accumulated Investment in Mainland China as of March 31, 2025	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on Investment
\$ 873,235	\$ 873,235	\$ 6,916,572

Note 1: The methods for engaging in investment in mainland China include the following:

- 1) Direct investment in mainland China.
- 2) Indirect investment in mainland China through companies registered in a third region (specify the name of the company in third region).
- 3) Other methods.

Note 2: The investment income (loss) recognized in current period:

1. No investment income (loss) has been recognized due to the investment is still in the development stage.
2. The investment income (loss) was determined based on the following basis:
 - (A) The financial report was reviewed and certified by an international accounting firm in cooperation with an accounting firm in the ROC.
 - (B) The financial statements were reviewed by the parent company's auditors.
3. Recorded as financial assets at fair value through other comprehensive income.

Note 3: The Company invested in Shanghai Grape King Enterprise Co., Ltd. through subsidiary GRAPE KING INTERNATIONAL INVESTMENT INC. (BVI).

Note 4: The Company indirectly invested in Shanghai Rivershine Ltd. through its subsidiary, GRAPE KING INTERNATIONAL INVESTMENT INC. (BVI).

Note 5: The Company directly invested in Shanghai Changhong Biotechnology Co., Ltd. Shanghai Changhong Biotechnology Co., Ltd is currently undergoing its liquidation procedures in November 2022, resulting in a recoverable amount less than the amount of the Company's investment, the Company recognized investment losses of \$2,538 thousand for the year ended December 31, 2022.

Note 6: The Company invested in Shanghai Xinquan Biotechnology Co., Ltd. through subsidiary Shanghai Rivershine Ltd..

Note 7: The Company invested in Shanghai Pujun Trading Co., Ltd. through subsidiary Shanghai Grape King Enterprise Co., Ltd..

Note 8: The Company invested in Shanghai Puxun Supply Chain Management Co., Ltd. through its subsidiary Shanghai Grape King Enterprise Co., Ltd.

Note 9: The Company invested in Shanghai Puyou Trading Co., Ltd. through its subsidiaries Shanghai Grape King Enterprise Co., Ltd. and Shanghai Pujun Trading Co., Ltd.

Note 10: The Company invested in Shanghai Puguang Trading Co., Ltd. through its subsidiary Shanghai Grape King Enterprise Co., Ltd.

Note 11: The current investment gain (loss) recognized by Shanghai Grape King Enterprise Co., Ltd. includes the current profit of Shanghai Pujun, Shanghai Puxun, PUBAI, Shanghai Puyou, and Shanghai Puguang, recognized based on the shareholding ratio.

Note 12: The current investment gain (loss) recognized by Shanghai Pujun Trading Co., Ltd. includes the current profit of Shanghai Puyou, recognized based on the shareholding ratio.

(Concluded)